HUE025374T2 - Új béta-aktin és RPS21 promóterek és alkalmazásaik - Google Patents

Description

• ELDER P K ETAL: "EVIDENCE THAT THE FUNCTIONAL BETA ACTIN GENE IS SINGLE COPY IN MOST MICE AND IS ASSOCIATED WITH 5’ SEQUENCES CAPABLE OF CONFERRING SERUM AND CYCLOHEXIMIDE-DEPENDENT REGULATION" MOLECULAR AND CELLULAR BIOLOGY, vol. 8, no. 1,1988, pages 480-485, XP002312116 ISSN: 0270-7306

• KIM TEOAN ET AL: "Gene transfer in bovine blastocysts using replication-defective retroviral vectors packaged with gibbon ape leukemia virus envelopes" MOLECULAR REPRODUCTION AND DEVELOPMENT, vol. 35, no. 2, 1993, pages 105-113, XP009042067 ISSN: 1040-452X • NAKAJIMA-IIJIMA S ET AL: "MOLECULAR STRUCTURE OF THE HUMAN CYTOPLASMIC BETA ACTIN GENE INTERSPECIES HOMOLOGY OF SEQUENCES IN THE INTRONS" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 82, no. 18,1985, pages 6133-6137, XP002312177 ISSN: 0027-8424

Description

Field of the Invention [0001] This invention relates to regulatory gene elements such as promoters and uses thereof, for example, for expression of proteins. More specifically, this invention relates ß-actin and ribosomal protein S21 gene promoters.

Background of the Invention [0002] Every eukaryotic gene contains regulatory elements driving transcription of that gene. Such regulatory elements include promoters, which are typically positioned immediately upstream of the coding sequence in a gene. Promoters regulate transcription by providing binding sites for transcription factors, which are a part of the transcription machinery. Promoters are commonly used to express proteins in cell culture and in vivo. Many promoters are known and used for expression of proteins in various expression systems. Examples of promoters include cytomegalovirus (CMV) immediate early promoter, Rous sarcoma virus genome large genome long terminal repeats (RSV), Simian Virus 40 (SV40) promoter, interferon gene promoter, metallothionein promoter, and the thymidine kinase promoter and others, e.g., as described in Fernandez et a/. (1999) Gene Expression Systems, Academic Press. Flowever, there is still a need in the art to provide promoters that are capable of generating high levels of expression and/or sustain expression for an extended period of time.

[0003] ß-actin is a structural protein and is usually expressed in all species, from protozoa to eukaryotes, including humans. The human and chicken ß-actin promoters have been previously described. The ß-actin promoter, in general, shows a more ubiquitous activity than the CMV promoter which is widely used (Xu et al. (2001) Gene 272: 149-156). The chicken ß-actin promoter was shown to exhibit a higher activity than viral CMV and SV40 promoters but only when it is linked to a CMV enhancer sequence (Xu et al., supra).

[0004] The ribosomal protein S21 (rpS21 ) which is associated with the 40S subunit of the ribosome. The promoter of the human rpS21 gene was previously identified (GenBankO accession No. AJ250907). Similarly to most ribosomal gene promoters, it lacks conventional transcription elements such as the TATA box and CAAT sequence (Smirnova et al. (2000) Bioorg. Khim. 26 (5): 392-396).

[0005] Beddington R S P et al. (Development; Volume 106; 1989; pages 37-46) describes an in situ cell marker which can be used to follow cell fate. The authors state that to create such a marker a transgenic mouse strain which carries 6 copies of the Escherichia colilac Zgene under the control of the rat ß-actin promoter was made by pronuclear injection of DNA.

[0006] Breitbart A S et al. (Annals of Plastic Surgery; Volume 43 No. 6; December 1999; pages 632-639) describes cloning the human PDGF-B gene into retroviral vectors under control of either the cytomegalovirus promoter or the rat ß-actin promoter.

[0007] Nudel U et al. (Nucleic Acids Research; Volume 11 Number 6; 1983; pages 1759-1771) relates to determination of the nucleotide sequence of the rat ß-actin gene. The authors state that the ß-actin gene codes for a protein identical to the bovine ß-actin, has a large intron in the 5’ untranslated region 6 nucleotides upstream from the initiator ATG and 4 introns in the coding region at codons specifying amino acids 41/42, 121/122, 267, and 327/328.

[0008] Database Accession No. U20114 (Database EMBL EBI; 21 April 1995) relates to the sequence of the ß-actin gene from Chinese hamster.

[0009] Elder P K et al. (Molecular and Cellular Biology; Jan 1988, p. 480-485) states that hybridisation to synthetic oligonucleotides representing conserved regions in the promoter and first intron of several vertebrate ß-actin genes was used to discriminate between what appears to be a single functional ß-actin gene and numerous pseudogenes in the mouse genome. The authors state that a plasmid termed pß5’-Gem4 was constructed by using a 4.5kb EcoRI-Sall fragment representing the 5’ end of the mouse ß-actin gene.

SUMMARY OF THE INVENTION

[0010] The present disclosure provides novel ß-actin promoters that have a low level of sequence homology to previously known ß-actin promoters (such as, e.g., human and chicken). The present disclosure further provides novel rpS21 promoters that have a low level of sequence homology to previously known rpS21 promoters (such as, e.g., human and mouse).

[0011] The present disclosure is based, in part, on the discovery and isolation of ß-actin and rpS21 promoters from a Chinese hamster ovary (CHO) cell line. This invention is further based, in part, on an observation that the hamster ß-actin promoter has a significantly higher activity than the CMV promoter. The present disclosure is further based, in part, on an observation that the rpS21 promoter is at least as active as the hamster ß-actin promoter when used forexpressing certain genes. The present disclosure provides nucleotide sequences for these promoters and includes variants of the nucleotide sequences having promoter activity. In some instances, a ß-actin promoter of the present disclosure is derived from a rodent, for example, hamster, rat, and mouse. The rpS21 promoter is typically derived from a hamster.

[0012] The present disclosure further, provides vectors comprising a ß-actin or a rpS21 promoter of the present disclosure operably linked to a heterologous nucleic acid. In certain instances, a vector of the present disclosure comprises a promoter that is operably linked to a heterologous nucleic acid which encodes a heterologous expression product such as, e.g., a therapeutic protein or a fragment thereof. In illustrative instances, the expression product is acid sphinogo-myelinase (ASM), a-glucosidase (GAA), or tissue plasminogen activator (tPA).

[0013] The invention also provides host cells transfected with a vector of the invention. In illustrative embodiments, the host cell is a mammalian cell such as, e.g., CHO, HEK, and BHK.

[0014] Methods for producing a protein are also provided. Methods for producing a protein include, for example, culturing a cell transfected with a vector comprising a ß-actin promoter and/or a rpS21 promoter of the present disclosure operably linked to a heterologous nucleic acid encoding a protein, and recovering the protein. In some instances, the heterologous expression product is a secretory protein, which is recovered from the medium. In illustrative instances, the protein is ASM, GAA, ortPA.

[0015] On the basis of the disclosure contained herein, the present invention provides an isolated ß-actin promoter that is chosen from the nucleotide sequences set forth in SEQ ID NOs: 1 or 3, or a variant thereof having promoter activity, wherein said variant is a nucleotide sequence having at least 95% identity to a nucleotide sequence set forth in SEQ ID NO: 1 or 3 over the entire length of that reference sequence.

[0016] The present invention further provides a method of producing a protein, wherein said method comprises: (a) culturing a host cell transfected with a vector comprising a promoter according to the present invention, wherein said promoter is operably linked to a nucleic acid molecule encoding said protein; and (b) recovering said protein.

[0017] Further embodiments of the present invention are set forth in the appended claims.

BRIEF DESCRIPTION OF THE FIGURES

[0018]

Figure 1A shows an alignment between portions of nucleotide sequences of a hamster ß-actin promoter (SEQ ID NO: 1) and a rat ß-actin promoter (SEQ ID NO: 2), demonstrating a 79% identity between nucleotide (nt) 487 to nt 893 of SEQ ID NO: 1 and nt 1 to nt 417 of SEQ ID NO: 2. The rat ß-actin promoter (SEQ ID NO: 2) has a 67% identity over the entire length of hamster ß-actin promoter (SEQ ID NO: 1).

Figure 1 B shows an alignment between portions of nucleotide sequences of a hamster ß-actin promoter (SEQ ID NO: 1) and a rat ß-actin promoter (SEQ ID NO: 2), demonstrating an 83% identity between nt 1047 to nt 3006 of SEQ ID NO: 1 and nt 546 to nt 2493 of SEQ ID NO: 2.

Figure 2A shows an alignment between portions of, nucleotide sequences of a hamster ß-actin promoter (SEQ ID NO:1) and a mouse ß-actin promoter (SEQ ID NO:3), demonstrating an 84% identity between nt 33 to nt 487 of SEQ ID NO:1 and nt 1 to nt 449 of SEQ ID NO:3. The mouse ß-actin promoter sequence (SEQ ID NO:3) has an 80% identity over the entire length of hamster ß-actin promoter sequence of SEQ ID NO:1.

Figure 2B shows an alignment between portions of nucleotide sequences of a hamster ß-actin promoter (SEQ ID NO:1) and a mouse ß-actin promoter (SEQ ID NO:3), demonstrating an 83% identity between nt 996 to nt 3006 of SEQ ID NO:1 and nt 921 to nt 2953 of SEQ ID NO:1.

Figure 3 shows an alignment between portions of nucleotide sequences of a hamster ß-actin promoter (SEQ I D NO:1) and a hamster ß-actin gene (Genbank® Accession No. U20114; SEQ ID NO:4), demonstrating a 98% identity between nt 1775 to nt 3006 of SEQ ID NO:1 and nt 1 to nt 1232 of SEQ ID NO:4. The hamster ß-actin gene sequence has a 40% identity over the entire length of the hamster ß-actin promoter sequence of SEQ ID NO:1.

Figure 4 shows an alignment between portions of nucleotide sequences of hamster ß-actin promoter (SEQ ID NO:1) and a previously known human ß-actin promoter (GenBank® Accession No. gi28337; SEQ ID NO:5), demonstrating a 94% identity between nt 113 to nt 148 of SEQ ID NO:1 and nt 38 to nt 73 of SEQ ID NO:5, an 83% identity between nt 362 to nt 433 of SEQ ID NO:1 and nt 303 to nt 374 of SEQ ID NO:5, a 90% identity between nt 1728 to nt 1764 of SEQ ID NO:1 and nt 1791 and nt 1830 of SEQ ID NO:5, and a 91% identity between nt 1797 to nt 1966 of SEQ ID NO:1 and nt 1840 to nt 2007 of SEQ ID NO:5. The human ß-actin promoter sequence (SEQ ID NO:5) shows a 10% identity over the entire length of the hamster ß-actin promoter sequence of SEQ ID NO:1.

Figure 5 shows an alignment between portions of nucleotide sequences of hamster ß-actin promoter (SEQ ID NO:1) and a previously known chicken ß-actin promoter (GenBank® Accession No. gi2170437; SEQ ID NO:6), demonstrating an 83% identity between nt 1878 to nt 1919 of SEQ ID NO:1 and nt 186 to nt 227 of SEQ ID NO:6. The chicken ß-actin promoter sequence (SEQ ID NO:6) shows a 1% identity over the entire length of the hamster ß-actin promoter sequence of SEQ ID NO:1.

Figure 6A depicts a Northern blot for galectin, ferritin, and ß-actin in CHO-K1 cells. Representative mRNAs were isolated from cells at 0, 4, 8, 10, and 15 hours following treatment of cells with actinomycin D.

Figure 6B depicts relative mRNA expression levels forgalectin, ferritin, and ß-actin genes. Representative mRNAs were isolated from cells at 0, 4, 8, 10, and 15 hours following treatment of CHO-K1 cells with actinomycin D. Figure 7A depicts relative promoter strengths as measured in transient transfection assays in CHO-K1 cells for the following promoters: CMV, human EF-1, hamster GAPDH, hamster rpS21_and hamster ß-actin. The representative promoters were cloned upstream of a red fluorescent protein (RFP) gene in the pDsRED-1 plasmid. The mean fluorescence was measured by FACS.

Figure 7B depicts relative promoter strengths as measured in stable transfection assays in CHO-K1 cells for the following promoters: CMV, human EF-1, hamster GAPDH, hamster rpS21, and hamster ß-actin. The representative promoters were cloned upstream of a red fluorescent protein (RFP) gene in the pDsRED-1 plasmid. The mean fluorescence was measured by FACS.

Figure 8A depicts the expression of acid sphingomyelinase (ASM) protein in media from three pools of CHO-DXB11 cells transfected with a vector containing the ASM cDNA operably linked to either the CMV promoter or the hamster ß-actin promoter. The expression of ASM was assessed in an enzymatic activity assay for ASM.

Figure 8B depicts the expression of a-glucosidase (GAA) protein in media from three pools of CHO-DXB11 cells transfected with a vector containing the GAA cDNA operably linked to either the CMV promoter or the hamster ß-actin promoter. The expression of GAA was assessed in an enzyme activity assay for GAA.

Figure 9 depicts the expression of tPA protein in media from pools of CHO-DXB11 cells transfected with a vector containing the tPA cDNA operably linked to the hamster ß-actin promoter. The expression of tPA was assessed using ELISA.

DETAILED DESCRIPTION OF THE INVENTION

[0019] In order that the present invention be more readily understood, certain terms are first defined. Additional definitions are set forth throughout the detailed description.

[0020] The term "promoter" refers to a regulatory element that directs the transcription of a nucleic acid to which it is operably linked. A promoter can regulate both rate and efficiency of transcription of an operably linked nucleic acid. A promoter may also be operably linked to other regulatory elements which enhance ("enhancers") or repress ("repressors") promoter-dependent transcription of a nucleic acid. The term "operably linked" refers to a nucleic acid placed in a functional relationship with another nucleic acid. A promoter is usually positioned 5’ (i.e., upstream) of a transcription initiation site in the nucleic acid. A promoter, however, may include sequences 3’ (i.e., downstream) of the transcription initiation site. A promoter may also encompass regions both 5’ and 3’ of the transcription initiation site of the operably linked nucleic acid.

[0021] The term "promoter activity" refers to the ability of a promoter to initiate transcription of a nucleic acid to which it is operably linked. Promoter activity can be measured using procedures known in the art or as described in the Examples. For example, promoter activity can be measured as an amount of mRNA transcribed by using, for example, Northern blotting or polymerase chain reaction (PCR). Alternatively, promoter activity can be measured as an amount of translated protein product, for example, by Western blotting, ELISA, colorimetric assays such as, e.g., Bradford assay (Bradford (1976) Anal. Biochem., 72:248), and various activity assays, including reporter gene assays and other procedures known in the art or as described in the Examples.

[0022] The term "vector" refers to viral or non-viral, prokaryotic or eukaryotic, deoxyribonucleic acid, ribonucleic acid or a nucleic acid analog, that is capable of carrying another nucleic acid. A vector may either carry a nucleic acid into a cell, referred to as "host cell," so that all or a part of the nucleic acid is transcribed or expressed. Alternatively, a vector may be used in an in vitro transcription assay. Vectors are frequently assembled as composites of elements derived from different viral, bacterial, or mammalian genes. Vectors contain various coding and non-coding sequences including sequences coding for selectable markers (e.g., an antibiotic resistance gene), sequences that facilitate their propagation in bacteria, or one or more transcription units that are expressed only in certain cell types. For example, mammalian expression vectors often contain both prokaryotic sequences that facilitate the propagation of the vector in bacteria and one or more eukaryotic transcription units that are expressed only in eukaryotic cells. It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc.

[0023] Vectors include, for example, plasmids, phagemids, and viral vectors. Vectors that have an existing promoter can be modified by standard recombinant DNA techniques known in the art to replace the promoter with any of promoter sequences set forth in SEQ ID NOs:1,2, 3, or 39 or a variant thereof. In general, suitable vectors can either be chosen from those that are commercially available or they can be constructed using standard recombinant DNA techniques known in the art. (See, e.g., Molecular Cloning: A Laboratory Manual: 2nd edition, Sambrook et al., 1989, Cold Spring Harbor Laboratory Press.) [0024] The terms "transformation" and "transfection" refer to intracellular introduction of a nucleic acid. A nucleic acid can be introduced into a plant or an animal cell or a prokaryotic or eukaryotic cell by a number of methods known in the art or described herein.

[0025] The term "isolated" refers to a deoxyribonucleic acid, a ribonucleic acid, or a nucleic acid analog having a polynucleotide sequence that is separated from other nucleic acid sequences in such a way that does not naturally occur. An isolated nucleic acid encompasses nucleic acids that may be partially or wholly chemically or recombinantly synthesized and/or purified by standard techniques known in the art.

[0026] The term "variant" in reference to a promoter sequence refers to a nucleotide sequence that is substantially identical over the entire length to the promoter sequence or to its complementary strand over the entire length thereof, provided that the variant has promoter activity.

[0027] Variants of ß-actin promoters may be the same length as the nucleotide sequences of SEQ ID NOs:1,2, or 3, or shorter, so long as they are at least 1250 nucleotides in length. Variants of rpS21 promoters may be the same length as the nucleotide sequence of SEQ ID NO:39, or shorter, so long as they have promoter activity. Variants of the ß-actin promoter can be naturally occurring, for example, naturally occurring ß-actin promoters isolated from species other than human and chicken, or they can be generated artificially. The identity between the hamster ß-actin promoter set forth in SEQ ID NO:1 and a variant thereof, when optimally aligned, is at least 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% over the entire sequence of SEQ ID NO:1 from nt 1 to nt 3007. Similarly, the identity between the rat ß-actin promoter set forth in SEQ ID NO:2 and a variant thereof is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% over the entire sequence of SEQ ID NO:2 from nt 1 to nt 2493. The identity between the mouse ß-actin promoter of SEQ ID NO:3 and a variant thereof is at least 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% over the entire length of SEQ ID NO:3from nt 1 to nt2953. Similarly, identity between the hamster rpS21 promoter set forth in SEQ ID NO:39 and a variant thereof, when optimally aligned, can be at least 40%, 50%, 55%, 60%, 65%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% over the entire length of SEQ ID NO:39from nt 1 to nt 1958.

[0028] Variants of ß-actin promoters may, for example, include orthologs of the ß-actin promoters in other species, including rodents and other mammals, but excluding human and chicken ß-actin promoters and known variants thereof. Variants of the promoters of the invention may also be found in other rodent species such as, for example, guinea pig, woodchuck, muskrat, gerbil, squirrel, chipmunk, prairie dog, beaver, porcupine, and vole.

[0029] The term "variants" further encompasses fragments of any one or more of promoters of the invention that have promoter activity. Variants of the ß-actin promoters are at least 1250 nucleotides in length. Variants of the ß-actin promoters of the invention can be derived, for example, by 5’ truncations of the hamster ß-actin promoter set forth in SEQ ID NO:1. In some embodiments, ß-actin promoter variants include sequences from nt 50 to nt 3000, from nt 100 to nt 3000, from nt 150 to nt 3000, from nt 200 to nt 3000, from nt 250 to nt 3000, from nt 500 to nt 3000, from nt 1000 to nt 3000, or from nt 1500 to nt 3000 of SEQ ID NO:1. In other embodiments, ß-actin promoter variants may be derived by 5’ truncations of the sequence set forth in SEQ ID NO:2 and include, for example, from nt 50 to nt 2490, from nt 100 to nt 2490, from nt 150 to nt 2490, from nt 200 to nt 2490, from nt 250 to nt 2490, from nt 500 to nt 2490, or from nt 1000 to nt 2490 of SEQ ID NO:2. ß-actin promoter variants may also be derived by 5’ truncations of the sequence set forth in SEQ ID NO:3 and include, for example, from nt 50 to nt 2950, from nt 100 to nt 2950, from nt 150 to nt 2950, from nt 200 to nt 2950, from nt 250 to nt 2950, from nt 500 to nt 2950, from nt 1000 to nt 2950, or from nt 1500 to nt 2950 of SEQ ID NO:3. Longer fragments of the hamsterß -actin promoter can be derived, for example, by 5’ truncations of the longer hamster promoter nucleotide sequence set forth in SEQ ID NO: 7. Such variants include, for example, sequences from nt 50 to nt 3668, from nt 100 to nt 3668, from nt 150 to nt 3668, from nt200 to nt 3668, from nt250 to nt 3668, from nt 500 to nt 3668, or from nt 600 to nt 3668.

[0030] Variants of rpS21 promoters may be derived by 5’ truncations and/or 3 ’truncations of the sequence set forth in SEQ ID NO: 39. Such variants include, for example, sequences from nt 50 to nt 1958, from nt 100 to nt 1958, from nt 150 to nt 1958, from nt 200 to nt 1958, from nt 250 to nt 1958, from nt 500 to nt 1958, from nt 1000 to nt 1958, from nt 1 to nt 1900, from nt 1 to nt 1850, from nt 1 to nt 1800, from nt 1 to nt 1750, from nt 1 to 1700, from nt 1 to nt 1600, or from nt 1 to nt 1500.

[0031] In certain instances, a ß-actin promoter of the present disclosure comprises a contiguous stretch of at least 1250,1500,1550,1600,1650,1700,1750,1800,1850,1900,1950, 2000,2500, or 3000 nucleotides from SEQ ID NOs : 1,2, or 3. Such contiguous stretches of SEQ ID NOs: 1,2, and 3 may also contain a mutation (insertion or deletion) so long as the mutant sequence retains at least some functionality of the original sequence and the capacity to hybridize to the respective sequences of SEQ ID NOs: 1,2, or 3 under low, medium or high stringency conditions. A contiguous stretch of a ß-actin promoter can be derived by 5’ truncations of any of sequences set forth in SEQ ID NO: 1,2, 3, or 7 or variants thereof as described above.

[0032] In other instances, a rpS21 promoter of the present disclosure comprises a contiguous stretch of at least 500, 600,700,800,900,1000,1100,1200,1300,1400,1500,1600,1700,1800,1850, or 1900 nucleotides from SEQ ID NO: 39.

[0033] ß-actin promoter variants of the present disclosure further include nucleotide sequences that hybridize to the entire length of the ß-actin promoter sequences shown in SEQ ID NOs: 1,2, or 3, or their complements and that have at most 0, 1,2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45% base pair mismatches. rpS21 promoter variants of the invention include nucleotide sequences that hybridize to the entire length of the rpS21 promoter sequence shown in SEQ ID NO: 39, or its complement, and that have at most 0,1,2, 3, 4, 5, 10, 15, 20, 30, 40, 45, 50, 55, 60% base pair mismatches. The percentage of base pair mismatches can be determined by standard techniques known in the art or as described herein. The term "heterologous" when used in reference to a nucleic acid, means a nucleic acid other than the nucleic acid that a promoter is operably linked to in a naturally occurring genome. For example, the term "heterologous" refers to any nucleic acid other than the hamster ß-actin gene when such a nucleic acid is operably linked to a hamster ß-actin promoter. Likewise, the term "heterologous" refers to any nucleic acid other than the rat ß-actin gene when such a nucleic acid is operably linked to a rat ß-actin promoter. Similarly, the term "heterologous" refers to any nucleic acid when such a nucleic acid is operably linked to the mouse ß-actin promoter. Analogously, this term also refers to any nucleic acid other than the hamster rpS21 gene when such a nucleic acid is operably linked to a hamster rpS21 promoter.

[0034] The term "transgenic" refers to any animal containing genetically manipulated cells in which a promoter of the invention is no longer operably linked to the same nucleic acid as in a naturally occurring genome. The term "transgenic" encompasses, for example, an animal containing cells with a promoter of the invention or a variant thereof integrated within the animal’s chromosome. The term "transgenic" also encompasses an animal containing cells with an extrachro-mosomally replicating DNA sequence comprising a promoter of the invention or a variant thereof. The transgenic animal may be a mammal such as a rodent or human.

[0035] This disclosure is based, in part, on the discovery and isolation of novel promoters for the ß-actin and rpS21 genes. Specifically, this disclosure features rodent ß-actin promoters including, but not limited to, hamster, rat and mouse, and the hamster rpS21 promoter. This invention is based on the discovery and demonstration that ß-actin promoters of the invention have promoter activity that is higher than the CMV promoter’s activity, as described in the Examples. The present disclosure is further based on the discovery that the hamster rpS21 promoter is at least as active as the hamster ß-actin promoter when used for expressing certain genes.

[0036] The present disclosure provides nucleotide sequences for rodent ß-actin promoters, including hamster, rat, and mouse, and methods of use thereof. The present disclosure further provides methods for identification and Isolation of variants of promoters of the invention, including homologs and fragments of promoters that have promoter activity. Additionally, the present disclosure provides a nucleotide sequence for the hamster rpS21 promoter, and methods of use thereof.

[0037] In the experiments leading to the present invention, a genomic clone for the hamster ß-actin promoter was isolated from CHO cells following its identification as an active promoter by a technique called Serial Analysis of Gene Expression or "SAGE" (Valculesco et al. (1995) Science, 270: 484-487 and Valculesco et al. (1987) Cell, 88: 243-251). The SAGE technique can be used for transcription profiling of an entire genome, ß-actin promoter was identified as one of the most active promoters in CHO cells using SAGE. This led to the cloning of the promoter for ß-actin in CHO cells. A similar approach was used for the isolation of the hamster rpS21 promoter from CHO cells. This approach may be used for transcription profiling of other genomes to confirm that corresponding ß-actin promoters or rpS21 promoter are active in another genome. Such a promoter can be cloned using standard techniques known in the art or those described here. Variants of promoters of the present disclosure can be identified by hybridization to one or more of promoter sequences set forth in SEQ ID NOs: 1,2, 3, or 39. It is well known that the melting temperature (Tm) of a double-stranded nucleic acid decreases by 1-1.5°C with every 1% decrease in homology (see, e.g., Bonner et al. (1973) J. Mol. Biol., 81: 123). Species homologs, therefore, can be identified, for example, by hybridizing a putative nucleotide sequence with a nucleotide sequence of SEQ ID NOs: 1,2,3, or 39, or a variant thereof, and comparing the melting temperature of such a hybrid with the melting temperature of a hybrid comprising a nucleotide sequence of SEQ ID NOs: 1,2, 3, or 39, or a variant thereof and a complementary nucleotide sequence. The number of base pair mismatches can then be calculated for the test hybrid. Therefore, a smaller difference between the melting temperatures of the test hybrid and a hybrid containing a putative homolog of any one of sequences in SEQ ID NOs: 1,2,3, or 39, will indicate a greater homology between the putative nucleotide sequence and a promoter sequence of the present disclosure. For example, variants in other rodent species such as guinea pig, woodchuck, muskrat, gerbil, squirrel, chipmunk, prairie dog, beaver, porcupine, and vole, may exhibit a greater homology to promoters of the present disclosure and variants thereof.

[0038] A variety of factors are known to affect the efficiency of hybridization of two strands of nucleotide sequence. These may include, for example, length of nucleotide sequence, salt concentration and G/C content of the sequences. For example, for hybridization of long fragments of DNA, Howley et al. (1979) J. Biol. Chem., 254: 4876, determined that the melting temperature at which 50% of a DNA is hybridized to a complementary strand is defined by:

Tm = 81. 5 + 16.6 log M + 41 (% G + % C) -500/L - 0. 62F, where M is molar concentration of monovalent cations; (%G + %C) is the respective fraction of G and C nucleotides in the sequences; L is length of the hybrid DNA; and F is molar concentration of formamide.

[0039] Appropriate hybridization conditions can be selected by those skilled in the art with minimal experimentation as exemplified in Ausubel et al. (1995) Current Protocols in Molecular Biology, John Wiley & Sons, sections 2, 4, and 6. Additionally, stringent conditions are described in Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Press, chapters 7, 9, and 11.

[0040] A non-limiting example of low stringency hybridization conditions is as follows. Filters containing DNA are pretreated for 6 h at 40°C. in a solution containing 35% formamide, 5 x SSC, 50 mM Tris-HCI (pH 7.5), 5 mM EDTA, 0.1% PVP, 0.1% Ficoll™, 1% BSA, and 500 μg/ml denatured salmon sperm DNA. Hybridizations are carried out in the same solution with the following modifications: 0.02% PVP, 0.02% Ficoll™, 0.2% BSA, 100 μg/ml salmon sperm DNA, 10% (wt/vol) dextran sulfate, and 5-20 X 106 32P-labeled probe is used. Filters are incubated in hybridization mixture for 18-20 h at 40°C, and then washed for 1.5 hours at 55°C in a solution containing 2 X SSC, 25 mM Tris-HCI (pH 7.4), 5 mM EDTA, and 0.1 % SDS. The wash solution is replaced with fresh solution and incubated for an additional 1.5 hours at 60°C. Filters are blotted dry and exposed for autoradiography. Other conditions of low stringency well known in the art may be used (e.g., as employed for cross species hybridizations).

[0041] A non-limiting example of high stringency hybridization conditions is as follows. Prehybridization of filters containing DNA is carried out for 8 h to overnight at 65°C in bufFer containing 6 x SSC, 50 mM Tris-HCI (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll™, 0.02% BSA, and 500μg/ml denatured salmon sperm DNA. Filters are hybridized for 48 hours at 65°C in the prehybridization mixture containing 100 μg/ml denatured salmon sperm DNA and 5-20 x 106 cpm of 32P-labeled probe. Washing of filters is done at 37°C for 1 hours in a solution containing 2 x SSC, 0. 01% PVP, 0.01 % Ficoll™ , and 0. 01 % BSA. This is followed by a wash in 0.1 x SSC at 50°C for 45 minutes.

[0042] A non-limiting example of hybridization conditions of moderate stringency includes prewashing filters in 5 x SSC, 0. 5% SDS, 1.0 mM EDTA, pH 8.0; hybridizing in 50% formamide, 6 x SSC at 42°C; and washing filters in 0.5 x SSC, 0.1% SDS at 60°C.

[0043] Variants of the promoters of the present disclosure can also be identified by percent identity between nucleotide sequences for putative variants and the sequences set forth in SEQ ID NOs: 1,2, 3, or 39, or their complementary strands. Percent identity may be determined, for example, by visual inspection or by using various computer programs known in the art or as described in the Examples. For example, percent identity of two nucleotide sequences can be determined by comparing sequence information using the GAP computer program described by Devereux et al. (1984) Nucl. Acids. Res., 12: 387 and available from the University of Wisconsin Genetics Computer Group (UWGCG). Percent identity can also be determined by aligning two nucleotide sequences using the BLAST@ program (www. ncbi. nim. nih. gov/BLAST) as described byTatusova etal. (1999) FEMS Microbiol. Lett., 174:247. For exam pie, for nucleotide sequence alignments using the BLAST@ program, the default settings are as follows : reward for match is 2, penalty for mismatch is-2, open gap and extension gap penalties are 5 and 2 respectively, gap x dropoff is 50, expect is 10, word size is 11, and filter is OFF.

[0044] Promoters of the present disclosure identified by sequence identity include, for example, sequences set forth in SEQ ID NOs: 2 and 3 for rat and mouse ß-action promoters, that show 67% and 80% identity, respectively, to nt 1 to nt 3007 of hamster ß-actin promoter sequence set forth in SEQ ID NO : 1. Additional variants can be readily identified using the various techniques described herein and those known in the art.

[0045] Percent identity between the hamster ß-actin promoter (SEQ ID NO: 1) and known ß-actin promoters can be determined as described. For example, when SEQ ID NO: 1 is compared to the human ß-actin promoter (SEQ ID NO: 5) using BLAST@ sequence alignment with default parameters, it exhibits only about a 10% identity over the entire length of SEQ ID NO: 1. Similarly, when SEQ ID NO : 1 is compared to the chicken ß-actin promoter (SEQ ID NO: 6), it exhibits only about a 1 % identity over the entire length of SEQ ID NO:1. Due to such low levels of homology, the human and the chicken ß-actin promoters are not considered to be variants of the hamster ß-actin promoter sequence of SEQ ID NO:1. Further, the 3’ portion of SEQ ID NO:1 shows significant homology to the 5’ portion of the hamster ß-actin gene sequence (GenBank® Accession No. U20114; SEQ ID NO:4). In particular, the first 1232 nucleotides of SEQ ID NO:4 show a 98% identity with the 3’ portion of SEQ ID NO:1, as depicted in Figure 3. This identity is in the region of the first intron in the hamster ß-actin gene. Overall, SEQ ID NO:4 shows only 40% identity over the entire length of SEQ ID NO:1. Furthermore, no promoter activity has been described for SEQ ID NO:4, or fragments thereof.

[0046] Using BLAST@ sequence alignment with default parameters, no homology is detected between the previously known human rpS21 promoter (nt 1-2344 of GenBank® Accession No. AJ250907) and nt 1 to 1958 of hamster rpS21 promoter of SEQ ID NO:39. Very low level of homology is detected between hamster rpS21 promoter of SEQ ID NO:39 and mouse genomic DNA that spans the mouse rpS21 gene (GenBank® Accession No. NT_039212). There are two regions of homology in the mouse sequences. The first is from nt 1775 to nt 1945 of SEQ ID NO:39 (137 out of 172 nts match). The second is from nt 580 to nt 851 of SEQ ID NO:39 (208 out of 274 nts match). These two regions of homology are separated by 923 nts in the hamster sequence (SEQ ID NO:39) and by 1745 nts in the mouse genomic sequence (NT_039212).

[0047] Accordingly, in some instances, an isolated promoter or a variant thereof having promoter activity comprises the nucleotides sequence (s) as set out from nt 1775 to nt 1945 of SEQ ID No: 39 and/or from nt 580 to nt 851 of SEQ ID NO: 39. Optionally, such a promoter or variant further comprises all or a portion of SEQ ID NO: 39 as set out from nt 852 to nt 1774.

[0048] Nucleotide sequences set forth in SEQ ID NOs: 1,2,3, or 39, or variants thereof, can be used as probes for screening genomic libraries for the isolation of genomic sequences that hybridize to one or more of sequences set forth in SEQ ID NOs: 1,2, 3, or 39, or variants thereof.

[0049] A promoter, according to the invention, or a variant thereof is operably linked to a heterologous nucleic acid which it expresses. The promoter can be used either alone or in combination with other regulatory elements such as, for example, enhancers and repressors. Alternatively, such a promoter can be integrated into the genome of a host cell or animal, thereby to express an endogenous gene in the host. A promoter according to the invention can be used in a vector for expression of heterologous nucleic acids. In certain embodiments, the heterologous nucleic acid encodes a therapeutic protein. Examples of therapeutic proteins include, but are not limited to, a-glucosidase, acid sphingomyelinase, insulin, tissue plasminogen activator, thyrogen stimulating hormone, erythropoietin, glucocerebrosidase, a-galac-tosidase and various antibodies. Examples of antibodies include but are not limited to, antibodies that bind members of the TGF-ß family such as, for example, TGF-ß-1,2, and 3.

[0050] This invention further provides vectors comprising a promoter of the invention or a variant thereof which has promoter activity. In some embodiments, vectors of the invention include a suitable restriction enzyme site downstream of the promoter for insertion of the heterologous nucleic acid. Such a restriction enzyme site may include a restriction site for a single restriction enzyme or it may include restriction sites for a variety of restriction enzymes in order to facilitate insertion of many different heterologous nucleic acids. A vector according to the invention may also contain a polyade-nylation sequence downstream of the site for inserting a heterologous nucleic acid. Vectors comprising promoters of the invention may also contain prokaryotic DNA elements for bacterial replication and an antibiotic selection marker for growth and selection of the vector in bacterial cells and additional DNA elements that control processing of transcripts such, e.g., termination signals. Vectors may further contain DNA sequences to direct secretion of a protein outside host cells.

[0051] In certain embodiments, a vector containing a promoter sequence of the invention is a bicistronic vector. Bicistronic vectors are designed, such that two nucleic acids can be transcribed to yield a single transcript. Such a transcript usually contains a first portion which is translated into one protein and a second portion translated into a second protein. One protein can be a protein of interest such as, a therapeutic protein, and a second protein may be used as a selectable marker. Bicistronic vectors usually contain a promoter and an internal ribosome entry site or 1RES positioned between two nucleic acids. This permits transcription of the two nucleic acids as a single bicistronic mRNA. In this manner, a vector can be constructed that includes a ß-actin promoter of the invention or a variant thereof and an 1RES between two heterologous nucleic acids. A bicistronic vector containing a ß-actin promoter of the invention or a variant thereof can be used for expressing a therapeutic protein such as, for example, acid sphinglomyelinase or a-glucosidase, in conjunction with a reporter gene.

[0052] The present disclosure further provides assays for identification of those variants of ß-actin and rpS21 promoters of the present disclosure that have promoter activity. For example, a promoter of the invention or variant thereof is inserted in a suitable vector upstream of a reporter gene and the expression of the reporter gene is used as a determinant of promoter activity. For example, for identification of variants of promoters of the invention that have promoter activity, such a variant is cloned upstream of a reporter gene. A reporter gene may encode an enzyme which catalyzes a reaction which produces a visually detectable signal. Examples of such reporter genes include ß-galactosidase and luciferase. Examples of other reporter genes include alkaline phosphatase, opaline synthase, octopine synthase, ß-glucoronidase, chloremphenicol acetyltransferase. In the Examples set forth below, a reporter gene encoding a Discosoma striata red fluorescent protein (RFP) is used for measuring promoter activity. Those skilled in the art, however, can use any suitable reporter gene and assay technique to determine promoter activity. Expression of a reporter gene from the promoter may be assayed in an in vitro expression system or it may be intracellular (e.g., in vivo).

[0053] The invention further provides host cells that have been transfected with a vector of the invention comprising a promoter operably linked to a heterologous gene. Such a host cell can be a prokaryotic cell or a eukaryotic cell. Host cells can either be cells in culture or be present in a non-human animal. Examples of host cells in culture include, but are not limited to, HeLa cells, CHO cells, NS0, HEK cells, BHK cells, NIH-3T3, MDCK cells, and COS cells. Host cells in culture can be grown either in suspension or on microcarriers, as described in the Examples.

[0054] Many suitable methods can be used for introducing nucleic acids of the invention into a host cell. Vectors comprising promoter sequences of the invention can be introduced into either prokaryotic or eukaryotic cells. Examples of techniques that may be used for introduction of nucleic acids into eukaryotic cells include, for example, calcium phosphate precipitation, DEAE-Dextran transfection, electroporation, liposome-mediated transfection, transduction using viral vectors, etc.

[0055] Many suitable expression systems can be employed for the production of proteins using promoters of the invention. One such expression system employs a dihydrofolate reductase (DHFR) gene which is introduced into the vector comprising a promoter of the invention or a variant thereof operably linked to a heterologous nucleic acid. Alternatively, an expression vector expressing DHFR can be co-transfected into the host cell, if a DHFR-deficient cell is used for expression. When increasing concentrations of methotrexate (MTX), a competitive inhibitor of the essential enzyme DHFR, are applied to’the transfected cells, only cells with higher expression levels of DHFR survive. As MTX levels are increased further, only cells which amplify the copy number of the DHFR gene survive. In this way, by increasing the copy number of the vector comprising the promoter, increased expression of the heterologous nucleic acid can be achieved, thereby leading to increased protein production. Asecond expression system employs a glutamine synthetase (GS) gene that is introduced into the vector comprising a promoter of the invention or a variant thereof operably linked to a heterologous nucleic acid. Addition of a competitive inhibitor of GS, e.g., methionine sulphoximine (MSX), is used for increasing the copy number of the vector leading to increased protein production.

[0056] Any suitable prokaryoticor eukaryotic expression system can be used for expression of proteins using promoters of the invention. Examples of expression systems include, but are not limited to, plant, baculovirus, yeast, bacterial, drosophila, mammalian and cell free expression systems. Standard methods for introducing expression vectors into mammalian, bacterial, yeast, insect and plant cells are provided, for example, by Ausubel (1995), supra.

[0057] In certain embodiments, promoters of the invention and variants thereof are used in methods of gene therapy. For example, a promoter of the invention or a variant thereof is cloned into a viral or a non-viral gene therapy vector such that it is operably linked to a gene of interest. The promoter drives expression of the gene encoding a therapeutic protein when the vector is delivered to a subject, e.g., a human patient.

[0058] The following examples provide illustrative embodiments of the invention. One of ordinary skill in the art will recognize the numerous modifications and variations that may be performed without altering the spirit and scope of the present invention. Such modifications and variations are encompassed within the scope of the invention. The examples do not in any way limit the invention.

EXAMPLES

[0059] The following describes materials and methods used in the subsequent Examples. A. Culturing ofCHO-K1 cells [0060] CHO-K1 cells were obtained from American Type Culture Collection (Manassas, VA) (ATCC No. CRL-9618). Cells were cultured in 250 ml spinner cultures containing 15 g/L DE-52 microcarriers (Whatman, Kent, UK) in 925 cell culture medium supplemented with 10% donor calf serum (DCS) (Invitrogen). Cells were maintained at 37°C using a 20-40% 02 and 5% C02 overlay and agitated at approximately 60 rpm for six days. Following growth of cells in the presence of serum, cultures were subjected to a daily 80% (v/v) replacement with serum-free 925 medium. Cells were grown in serum-free medium for 11 days prior to extraction of RNA from cells. For the determination of mRNA half-life, 7 mg/L of actinomycin D was added to the cultures in the serum-free phase. B. RNA Extraction and Analysis [0061] RNA was isolated from CHO-K1 cells using the RNAgents kit from Promega (Madison, Wl). Gene expression was analyzed by Northern blotting. For Northern blot analysis, 5 μg of RNA was separated by electrophoresis on a denaturing glycoxal/dimethylsulfoxide gel using a NorthernMax®-Gly kit. (Ambion, Austin, TX). The RNA was subsequently transferred to nylon membranes (Schleicher & Schuell, Dassel, Germany). The blots were probed with the following gene probes amplified by PCR: galectin (GenBank® Accession No. M96676, nt 14-383); ß-actin (Genbank® Accession No. U20114, nt 238-381); EF-1 (GenBank® Accession No. D00522, nt 7-192); rpS21 (GenBank® Accession No. X79059, nt 68-340); ferritin (GenBank® Accession No. M99692, nt 182-303) or a commercially available glyceryl-dehyde 3-phosphate dehydrogenase (GAPDH) fragment (Ambion, Austin, TX). Each PCR product was radiolabeled by random priming. PCR primers used for amplification of each of the genes are listed in Table 1. TABLE 1

(continued)

C. Transfection ofCHO-K1 Cells [0062] For transient transfection, CHO-K1 cells were plated on 6-well plates in 925 medium with 10% fetal bovine serum (FBS) (Invitrogen). The cells were grown to 50-75% confluency prior to transfection using Lipofectamine™ (Inv-itrogen). The pDsRED-1 plasmid (Clontech, Palo Alto, CA) was co-transfected with the pSV40-CD20 plasmid, which encodes a cell surface CD20 marker used to identify transfected cells. This pDsRED-1 plasmid encodes a Discosoma striata red fluorescent protein (RFP), the expression of which can be detected by FACS. Transfections were performed as per manufacturer’s instructions. Briefly, cells were incubated with lipid-DNA complexes for 16 hrs in serum free Opti-MEM™ medium (Invitrogen). The medium was replaced with 925 medium with 10% FBS, and cells were harvested 48 hours post-transfection. D. Fluorescence-Activated Cell Sorting Analysis [0063] For FACS analysis, 1x106 cells were trypsinized and washed with cold PBS containing 2% FBS. Cells were subsequently incubated with an FITC-labeled anti-CD20 antibody (Pharmingen, San Diego, CA) for 30 minutes on ice. Cells were then washed with cold PBS containing 2% FBS and resuspended in 1 ml of cold PBS/2% FBS. FACS analysis was performed using FACSCalibur™ (BD Biosciences, San Diego, CA). All CD20-positive events were evaluated for their red fluorescent protein mean fluorescence intensity to assess promoter strength. E. ASM Assay [0064] Media from cells transfected with a vector encoding acid sphingomyelinase (ASM) were incubated at 37°C with the synthetic substrate 2-(N-hexadecanoylamino)-4-nitrophenylphosphorylchlorine (Calbiochem, San Diego, CA) at the concentration of 12.5 mM in 250 mM sodium acetate, pH 5.5, containing 0.1 mM zinc acetate, 0.25 mg/ml bovine serum albumin (BSA) and 0.15% Tween 20. The reactions were stopped by the addition of 0.2 M glycine-NaOH containing 50% ethanol. The activity or amount of ASM was measured by the amount of 2-(N-hexadecanoylamino)-4-nitrophenolate produced using a colorimetric assay by measuring optical density at 415 nm. F. GAA Assay [0065] Media from cells transfected with a vector encoding a-glucosidase (GAA) were incubated at 37°C with the synthetic substrate p-nitrophenyl-D-a-glucopyranoside (Sigma, St. Louis, MO) at a concentration of 40 mM in 50 mM sodium acetate, pH 4.3, containing 0.1 % bovine serum albumin (BSA). The reactions were stopped by the addition of 0.3 M glycine, pH 10.6. The activity or amount of GAA was measured by the amount of p-nitrophenyl produced using a colorimetric assay by measuring optical density at 400 nm.

Example 1 : Identification of the B-Actin Promoter in CHO-K1 Cells [0066] Serial Analysis of Gene Expression (SAGE) was used to analyze the entire transcription profile of CHO-K1 cells that were grown in a serum-free perfused spinner culture.

[0067] The first step in SAGE involved synthesis of double stranded DNA from mRNA isolated from CHO-K1 cells using standard techniques. The cDNA was subsequently cleaved with a restriction endonuclease Nlalll, also called an anchoring enzyme, which is expected to cleave most transcripts at least once. The 3’ portion of each cleaved cDNA was isolated by binding to streptavidin beads. The cDNA pool was then divided in half and ligated via anchoring the restriction site to a linker containing a type II restriction endonuclease site (for example, Foki). Type II restriction endonucleases cleave at a defined distance up to 20 base pairs away from their asymmetric recognition sites. The type II enzyme is typically called a tagging enzyme. Cleavage of the ligation product with the tagging enzyme results in the release of the linker with short pieces of the cDNA. A combination of the anchoring and tagging enzymes yields a 10 base pair tag which is unique to a gene.

[0068] Using this approach, sequence tags for each gene were represented by the 3’-most Nlalll site followed by a unique 10 bp sequence. In instances where tags could not be assigned to known genes, a SAGE library cDNA was PCR amplified using the SAGE tag and a commonly used M13 forward primer (GTTTTCCCAGTCACGAC, SEQ ID NO:18). PCR products were subsequently cloned into the pCR2.1 vector (Invitrogen) and sequenced using standard techniques. Identification of genes was based on the homology of the sequence of PCR products to known sequences in GenBank® (www.ncbi.nlm.nih.gov/genbank).

[0069] A BLAST® alignment (www.ncbi.nlm.nih.gov/blast) of nucleotide sequences to their mouse and/or rat counterparts was performed to identify the gene from which the tag was derived. Of the sixteen most abundant tags identified in this analysis (Table 2), the gene for all but one tag was identified. Of these fifteen identified genes, five were mitochondrial in origin and three were nuclear repetitive elements. Occurrence of multiple copies of these genes in each cell was the likely cause of their abundance in the SAGE output. Such sequences were not considered for further evaluation. TABLE 2

[0070] Using this approach, promoters of four genes were identified as being the most active in CHO-K1 cells. These promoters were: ß-actin, ribosomal protein S21 (rpS21), elongation factor 1 (EF-1), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The high levels of these mRNAs in CHO-K1 cells could either be due to the promoter activity of their respective promoters or due to innate stability of the mRNAs. Although SAGE analysis provides a quantification of overall steady state levels for the mRNAs for genes, it does not distinguish between promoter activity of the gene and mRNA stability as the basis of the high expression of the mRNA. Thus, in order to distinguish between the two possibilities, half-life of mRNAs were measured. Briefly, expression of candidate genes was assessed by Northern blot analysis of CHO-K1 cells in spinner cultures at varying points following treatment of cells with actinomycin D.

[0071] Initially, the rpS21, GAPDH and EF-1 genes were analyzed and were all found to have relatively stable mRNAs with half-lives greater than 8 hours. These results suggested that the greater abundance of these mRNAs resulted from greater stability of the mRNAs and not necessarily greater activities of the respective promoters.

[0072] The half-life of galectin, ferritin, and ß-actin mRNAs was also measured by Northern blot analysis, as described above, at 0, 4, 8, 10, and 15 hours following treatment of cells with actinomycin D. A representative Northern blot is shown in Figure 6A. The relative mRNA levels are represented graphically in Figure 6B. These data show that although both galectin and ferritin had half-lives of greater than 8 hours, the ß-actin mRNA turned over more rapidly with a half-life of approximately 6 hours. Thus, the relative contribution of promoter strength to overall steady state mRNA levels was greater for ß-actin than the other candidates in CHO-K1 cells. Accordingly, under these conditions, the ß-actin promoter can be characterized as a strong promoter.

Example 2: Isolation and Characterization of the Flamster B-Actin and roS21 Promoters [0073] In light of the results described in Example 1, the candidate with the greatest abundance (rpS21) and the one with the most rapid mRNA turnover (ß-actin) were selected for further study. A A FIX II CHO-K1 genomic library (Strat-agene, LaJolla, CA) was screened to isolate genomic DNAs for hamster ß-actin and rpS21 promoters.

[0074] In order to isolate ß-actin and rpS21 genomic clones, the E. coli bacterial strains, XL1-Blue MRA (P2) were grown in LB medium containing 10 mM magnesium sulfate and 0.2% maltose. The bacterial cells were pelleted and resuspended in 10 mM magnesium sulfate at an absorbance reading of 0.5 at 600 nm. Approximately one million phage from the library were incubated with the bacterial cells for 15 minutes at 37°C. Molten agarose was added to the phage/bac-teria mixture and the bacteria were overlayed on agar-containing BioAssay plates (Nunc, Rochester, NY). Following the hardening of the top agarose, the plates were inverted and grown at 30°C overnight. Plates were subsequently chilled and overlayed twice with Genescreen Plus™ nylon filters (Perkin Elmer Life Sciences, Wellesley, MA). The nylon filters were denatured for 2 minutes in 0.1 M sodium hydroxide with 1.5 M sodium chloride and subsequently neutralized. Filters were UV cross-linked and probed.

[0075] A probe used for isolation of the hamster ß-action promoter was derived by random PCRfrom the 5’ end of the ß-actin gene (nt 238-381 ofGenBank® Accession No. U 20114). A probe used for the isolation of hamster rpS21 promoter was derived by PCR using primers set forth in SEQ ID NOs:12 and 13. Hybridizing phage for both ß-actin and rpS21 promoters were purified using standard techniques. The DNA from the phage isolated from the phage lysates was purified by sequential extractions with chloroform, phenol, phenol/chloroform (1:1), and lastly, chloroform.

[0076] For isolation of hamster ß-actin gene promoters, following ethanol precipitation, DNA was digested with restriction enzymes that had sites in the 5’ portion of the ß-actin hamster gene and subjected to Southern blotting using the same probe that was used to screen the genomic library.

[0077] Using this approach, an Avril fragment of approximately 7 kb and a Sail fragment of approximately 5.5 kb were generated, both of which hybridized to the probe. These were subsequently cloned into pBluescript II KS plasmid (Stratagene). The 7 kb Avril fragment has the ATCC Reference No. PTA-5309, deposited July 3,2003 with the American Tissue Culture Collection, P.O. Box 1549, Manassas, VA20108, U.S.A.

[0078] Plasmids containing Avril and Sail fragments were digested with Sfol to remove the 3’ end of the fragments which contained a portion of the open reading frame of the ß-action gene. These fragments were then cloned into the pDsRED-1 plasmid (Clontech) to create the constructs termed pDsRED-Avr (6.5kb) and pDsRED-Avr (5.1 kb). In order to generate a construct containing all of intron 1 of the ß-actin gene, PCR was performed using the following primers:

Forward: AGGCCCAGCTTGGG AC C AAG AC AG AA (SEQ ID NO:35)

Reverse: CGCGGATCCGGCGAACTATATCAGGGC (SEQ ID NO:36).

[0079] The PCR fragment generated two products: a predicted product of approximately 7 kb and a smaller unexpected 3 kb product. Both of these PCR products were cloned into the pDsRED-1 plasmid (Clontech) to generate the constructs pDsRED-Avr(1)-7 and pDsRED-Avr(1)-3.

[0080] Each of the fragments of the ß-action hamster promoter that were cloned into the pDsRED-1 plasmid (Clontech) were transfected into CHO-K1 cells. The relative promoter strengths of each of the hamster ß-actin promoter fragments were measured using FACS as described above. The results of the activity assays are summarized below.

[0081] Avr(1)-3 fragment of ß-action promoter which spans from nt -1970 to nt +1037 exhibited the highest promoter activity. The Avr(1 )-7 fragment which spans from nt -6000 to nt +1037 exhibited an activity that was 47% of the activity exhibited by Avr(1)-3. The Avr(6.5 Kb), Sal(5.1Kb), Actin(3 kb), and Actin-P(2.8 kb) fragments exhibited only 2%, 2%, 2%, and 0% promoter activity, respectively, as compared to the Avr(1)-3 fragment.

[0082] The Avr(1 )-3 frag ment was subsequently sequenced, and the sequence is set forth in SEQ ID NO: 1 .Additionally, the region 660 nt upstream of the 5’ of Avr(1) 3 was also sequenced. This longer sequence from nt -2622 to nt +1037 is set forth in SEQ ID NO:7.

[0083] For isolation of the rpS21 promoter, following isolation of DNAfrom the hybridizing phage, the DNA was amplified by PCR using the following primers:

Forward: AG CTCT AATACG ACT C ACT AT AG G G C (SEQ ID NO:40)

Reverse: CTCTAGGCCAGCGGAGCGCAG (SEQ ID NO:41).

[0084] The PCR product was cloned into the vector PCR2.1 (Invitrogen) and subsequently sequenced. The nucleotide sequence of the hamster rpS21 promoter is set forth in SEQ ID NO: 39. The promoter was excised using EcoRI sites flanking the cloning sites and cloned into the pDsRED1-1 vector (Clontech).

Example 3: Functional Comparison of the Hamster B-Actin and CMV Promoters [0085] The promoter activity of Avr (1)-3 was compared to that of the CMV immediate early promoter (Invitrogen) and the human EF-1 promoter (Invivogen).

[0086] CHO-K1 cells were transient transfected with either pDsRED-1 plasmid containing either Avr (1)-3, the CMV immediate early promoter upstream, or the human EF-1 promoter, each operably linked to the RFP gene. Expression of RFP was assessed by FACS 48 hours post- transfection.

[0087] As shown in Figure 7A, in cells transfected with Avr (1)-3, the ß-actin promoter sequence (SEQ ID NO: 1) showed a higher level of RFP expression as compared to either the CMV or EF-1 promoters. In particular, expression was approximately two-fold higher with Avr (1)-3 than with the CMV promoter.

[0088] In order to determine, whetherthis observed expression profile is sustainable in stable transfectants, transfected CHO-K1 cells were selected for two weeks with G418™. Expression of RFP in the surviving pools of cells was then assessed. As depicted in Figure 7B, similarly to transient transfected cells, the highest RFP expression was observed in cells transfected with Avr(1)-3, the ß-actin promoter sequence set forth in SEQ ID NO:1. Example 4: Activity of the Hamster ß-Actin Promoter in BHK-21 and HEK293 cells [0089] The activity of the hamster ß-actin promoter was compared to that of CMV promoter in BHK-21 (ATCC No. CCL 10) and HEK293 (ATCC No. CRL-1573) cells using stable transfection assays as described in Example 3. As seen previously in CHO-K1 cells, expression of RFP in BHK-21 cells was significantly higher when using the ß-actin promoter instead of the CMV promoter (Table 3). In HEK293 cells, the hamster ß-actin promoter resulted in expression of RFP at levels roughly equivalent to those of the CMV promoter. TABLE 3

Example 5: Rat and Mouse R-Actin Promoters [0090] Publicly available databases of nucleotide sequences were searched using default settings for potential homologs of the hamster ß-actin promoter sequence set forth in SEQ ID NO:1.

[0091] The 5’ portion of a ß-actin hamster gene (GenBank® Accession No. U21104; SEQ ID NO:4) exhibits 98% identity to the 3’ portion of the hamster ß-actin promoter sequence. This homology, however, is only 40% over the entire length of the hamster ß-actin promoter sequence set forth in SEQ ID NO:1. No promoter activity is known for this portion.

[0092] Previously known ß-actin promoters: human (GenBank® Accession No. gi28337A) and chicken (GenBank® Accession No. gi2170437) were aligned with the hamster ß-action promoterfor homology determination with the BLAST® program using default settings. The human and the chicken ß-actin promoter sequences had only 10% and 1% identity, respectively, to the hamster ß-actin promoter (SEQ ID NO:1).

[0093] A rat (Rattus norvegcus) genomic supercontig (GenBank® Accession No. NW_042778) was identified on chromosome 12 of the rat genome as containing a nucleotide sequence having a 67% identity over the entire length of SEQ ID NO:1.

[0094] Similarly, a contig (GenBank® Accession No. NT_039324) was identified on chromosome 5 of the mouse (Mus musculus) genome as having a 80% identity over the entire length of SEQ ID NO:1.

[0095] The sequence alignments of hamster ß-actin promoter sequence (SEQ ID NO:1) with the hamster gene sequence, and ß-actin promoters from human, chicken, rat and mouse are depicted in Figures 3,4, 5,1, and 2, respectively.

Example 6: Activities of the Rat and Mouse B-Actin Promoters [0096] The rat and the mouse promoter sequences set forth in SEQ ID NOs:2 and 3, respectively, are cloned into the pDsRED-1 plasmid (Clontech). The CMV promoter is also cloned upstream of the RFP gene in the pDsRED-1 plasmid.

These plasmids are transfected into CHO-K1 cell, or another cell line. Expression of the RFP is assessed by FACS 48 hours post-transfection.

[0097] Cells transfected with the rat or the mouse ß-actin promoter are expected to show a higher RFP expression than the CMV promoter under similar conditions.

Example 7: Expression of Proteins Using Flamster B-Actin Promoter [0098] To further evaluate activity of the hamster ß-actin promoter, an expression system utilizing dihydrofolate reductase (DHFR) selection and methotrexate (MTX) amplification was used. The vector pGZ6 was derived from the pCLHAXSV2DHFR plasmid, so as to contain the 3 kb hamster ß-actin promoter (SEQ ID NO:1) in addition to a DFIFR gene under the control of the SV40 early promoter. The pCLFIAXSV2DFIFR plasmid has been previously described by Cole et al. (1993) Biotechnology, 11:1014-1024. Briefly, the metallothionine (MT) promoter in the pCLHAXSV2DFIFR vector was replaced with the ß-actin promoter to create the pGZ6 vector. cDNAs for two proteins of therapeutic interest, acid sphingomyleinase (ASM) and a-glucosidase (GAA) wereoperably linked to the hamster ß-actin promoter. The ASM cDNA was obtained through the IMAGE™ consortium (GenBank® Accession No. AI587087). The cDNAfor GAA was obtained from Dr. Martinuik at the New York University School of Medicine. The nucleotide sequences of the ASM and GAA cDNAs are setforth in SEQ ID NOs:37 and 38, respectively. Similarly, the two cDNAs were also cloned downstream of the CMV promoter in a vector containing the same DFIFR expression cassette. The DFIFR-deficient CFIO-K1 cell line DXB11 was transfected in triplicate with both sets of expression vectors. After two weeks of selection in nucleotide-deficient media containing 20 nM MTX, a heterogeneous uncloned pools of cells were washed with PBS and transferred to serum-free media. Twenty four hours later, levels of ASM or GAA in the media were measured.

[0099] The results of one such experiment are demonstrated in Figures 8A and 8B. The levels of ASM generated from the hamster ß-actin promoter in the stable pools were from 2 to 15 times greater than with the CMV promoter, and in the case of the GAA pools, 2 to 5 times greater.

[0100] The stable pools were further used to evaluate the ability of the ß-actin promoter to sustain long-term protein expression. Typically, for industrial production of proteins, high expression is achieved by selecting cells with a higher gene copy number through a process that involves increasing the number of selection steps and/or concentration of MTX. In order to determine whether a higher expression could be achieved via this strategy with the ß-actin promoter (SEQ ID NO:1), the ASM pools initially selected at 20 nM MTX were amplified by selection for two weeks at ten-fold higher levels of MTX (200 nM). As summarized in Table 4, two of the three tested ß-actin pools showed 2 to 3-fold greater levels of ASM after amplification relative to the starting 20 nM pools. In contrast, only one of the CMV pools tested showed higher levels than the 20 nM pool, from which it was derived. Among the six ASM pools generated with either of the two promoters, the highest expressing ß-actin pool generated six times the amount of ASM obtained with the highest expressing pool generated with CMV promoter. This demonstrates that, at least under the conditions tested, the hamster ß-actin promoter is superior to the CMV promoter. TABLE 4

[0101] In a separate experiment, the hamster ß-actin promoter was used for expressing tissue plasminogen activator (tPA) protein, which is a thrombolytic agent used in patients fordissolving blood clots. CFIO-DXB11 cells were transfected with a pGZ6-tPA expression vector in which the hamster ß-actin promoter is operably linked to the tPA gene. Stable transfectants were selected by growth in nucleotide deficient medium containing 200 nM MTX. The resulting pool of uncloned cells was then subjected to 500 nM MTX to amplify transgene copy number. This pool of cells was removed from MTX, expanded and seeded on Cytopore™ 2 microcarriers in a 1 liter spinner culture. Cells were grown for 7 days in a serum containing medium. For the next 4 days, the serum was removed by daily 80% exchanges with serum free medium. Media harvests were then collected over 15 days and analyzed for tPA expression using a commercially available ELISA kit (TintElize® tPA kit, Biopool International, Inc., Ventura, CA). As depicted in Figure 9 of this experiment, the use of the hamster ß-actin promoter resulted in tPA expression at a concentration of about 30 mg/L per day. This result compares favorably to recently published reports in which about 30-40 mg/L of tPA was produced after 4-8 days using other promoters (Sengeret al. (2003) Biotechnology Progress 19: 1199-1209; Dowd et al. (2000) Biotechnology Progress 16:786-794).

Example 8: Production of Antibodies Using Hamster B-Actin Promoter [0102] In order to produce an antibody to a TGF-ß family member, nucleic acid encoding either an anti-TGF-ß antibody light chain or an anti-TGF-ß antibody heavy chain is cloned downstream of the hamster ß-actin promoter in two separate pGZ6 expression vectors.

[0103] The DHFR-deficient CHO-K1 cell line DXB11 is transfected in with both expression vectors. After two weeks of selection in nucleotide-deficient media containing MTX, levels of anti-TGF-ß antibody, including both the light chain and the heavy chain, are measured in the media.

Example 9: Expression of Proteins Using Hamster rpS21 Promoter [0104] The hamster rpS21 promoter activity was compared to the hamster ß-actin promoter activity for expression in CHO-DXB11 cells. CHO-DXB11 cells were transfected with expression vectors containing human a-glucosidase(rhGAA) operably linked to either the hamster rpS21 promoter of SEQ ID NO:39 (pGZ3IC-GAA) or hamster ß-actin promoter of SEQ ID NO:1 (pGZ6IC-GAA). In both cases the rhGAA gene was linked to the gene encoding a cell surface marker (CD20) through an internal ribosome entry site [0105] (1RES) sequence. After selection of cells with 0.2 μΜ MTX in nucleotide deficient medium, the cells were labeled with a FITC-conjugated antibody to CD20 and sorted by FACS for high expressing clones. Selected cells were plated in 96-well plates and expanded for evaluation of rhGAA expression. 38 clones were analyzed for the hamster rpS21 promoter, and 29 clones were analyzed for the hamster ß-actin promoter. Table 5 shows the distribution of expression ranges in the resulting clones for both promoters. TABLE 5

[0106] In a separate experiment, the hamster rpS21 promoter was used for expressing ASM in CHO-DXB11 cells. The activity of the rpS21 promoter was compared to activities of both ß-actin and CMV promoters. CHO-DXB11 cells were transfected in triplicate and either selected directly at 200 nM MTX, or initially selected at 20 nM MTX and then amplified for two weeks at 200 nM MTX, as discussed in Example 7. Levels of ASM were measured in the media as described. ASM expression in untransfected cells was undetectable.

[0107] As summarized in Table 6, all three rpS21 pools showed 2-to 3-fold greater levels of ASM after amplification relative to the starting 20 nM pools, from which they were derived. Further, the levels of ASM generated were higher than the levels generated with the CMV promoter(Example 7). TABLE 6

[0108] The levels of ASM expression generated with selection of the pools directly at 200 nM MTX are summarized in Table 7. TABLE 7

[0109] The levels of ASM generated from the hamster rpS21 promoter at 200 nM MTX were on average about 1 to 2 times greater than that with the CMV promoter. The ASM levels generated from the ß-actin promoter, on the other hand, were on average about 3 to 4 times greater than that with the CMV promoter. Thus, the rpS21 promoter was at least as active as the ß-actin promoter when used for expressing GAA, however, it exhibited lower activity than the ß-actin promoter when used to express ASM. Both promoters, however, were more active than the CMV promoter.

[0110] The specification is most thoroughly understood in light of the teachings of the references cited within the specification. The embodiments within the specification provide an illustration of embodiments of the invention and should not be construed to, limit the scope of the invention. The skilled artisan readily recognizes that many other embodiments are encompassed by the invention. The citation of any references herein is not an admission that such references are prior art to the present invention.

[0111] Unless otherwise indicated, all numbersexpressing quantities of ingredients, cell culture, treatment conditions, and so forth used in the specification, including claims, are to be understood as being modified in all instances by the term "about." Accordingly, unless otherwise indicated to the contrary, the numerical parameters are approximations and may vary depending upon the desired properties sought to be obtained by the present invention. Unless otherwise indicated, the term "at least "preceding a series of elements is to be understood to refer to every element in the series. Those skilled in the art will recognize, orbe able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

SEQUENCE LISTING

[0112] <110> ESTES, SCOTT ZHANG, WEIQUN GENZYME CORP.

<120> NOVEL B-ACTIN AND RPS21 PROMOTERS AND USES THEREOF <130> 7680.27-304 <140> <141 > <150> 60/480,768 <151 >2003-06-24 <160> 41 <170> Patentln version 3.2

<210 1 <211> 3007 <212> DNA <213> Artificial Sequence <220> <223> beta-actin promoter isolated from CHO cells <400> 1 gggaccaaga cagaaccata agccagtggg atagatcaga aatgttccag aggtgggatg 60 gggccagagt gcctgcccct tgaaccgtcc cagggaccag aggtgacaaa gtggcaacac 120 aggtcctgcc tgggaatctg gtctgctcct acttagtaaa gctgcctggt gtcacacaag 180 aggcccccac ttattcctgc acccctggtg gtaggtggcg tcttctcccc tgcagccacc 240 aggctcccct gagaacactg ccggcagtcc tcattgacag gcagtattcg ctctgcccca 300 cccccacctg tgaattgcag ggctggcagg tcctcaggca gctggcaaac cgcctgaaca 360 actgagagat acagggccag ggccagggca gtcccgtccc ccggaggcag ggaggggacg 420 tgctgggaaa gttctctctc tcaggcccag gttggtgact gcagaaggct tctgtcaaat 480 ctcttttgtg ggaaccacag agtagccctg aacgtggggg tgtgcttcca gtatactctg 540 gggtcaccct ttccatactg gaggcctctg caacttcaaa atgctctgct accaacctag 600 cacaaggaag ttggtccagc ctccccacgc agggccactg ctgcagtcca tatatggact 660 aagccttcct tggtttcaac acctacactc actgagcccc tactatgtgt atgcagagcc 720 gagacaggcc cgagcatctc atctgaagca cccttcttgc ctaaattcag ttttctgtca 780 ctttctccca ggaggtgtgt gtccctctaa gctaagccag gggtccctca cccctgcccc 840 actcccatcc ctagtgtagg tatcagctga agagcttcct gagcagaaca ctcttgggtg 900 ctgacatttt gataaatagg cccatgttta ggagagcagg ggtccggggg cgggagatct 960 tctctggtgg attgagggct ccaagaacta ctctttgagc acgctgcccc tcccagagtc 1020 cccacagcct ccagatggac tagaacacag ttcggctgtg gctgcacata actaacagag 1080 gatagatggt gggtcccagc ccaacagtgc ctggcaatca cccagagcca ccagctaacg 1140 gccttggctt agttttttgc ctgggtgtga tcaggcagcc ctccaaaact gcccggactc 1200 catgacaagt tttgcttgtt ctatagagca cagttccttt ctaggtctgg ggcaagggac 1260 atcgggagac atcttcctgc aacagctcca gtcactggac caccaggctc gccctgtctt 1320 tggtgtgtgg ccctgagtct cctaagtggc ccaaacctgt gaagacccct ccaaccacag 1380 ttttgcttct aaattgtacc ccaacacacc tagcaaattg aaaccccacc agaagtcccc 1440 cagatctggc tttccggcta ttgctggcaa gggggagtga ctcccggccc attcaatcca 1500 ggccccgcgt gttcctcaaa caagaagcca cgtaaacata aaccgagcct ccatgctgac 1560 ccttgcccat cgaggtactc aatgttcacg tgatatccac acccagaggg tcctggggtg 1620 ggtgcatgag ccccagaatg caggcttgat aaccgagacc ctgaatcggg cagtgtccac 1680 aagggcggag gcccagtcat gcatgttcgg gcctatgggg ccagcaccca acgccaaaac 1740 tctccatcct cttcctcaat ctcggctttc tctctctctc tctttttttt tttttatttt 1800 ttttttttgc aaaaggaggg gagagggggt aaaaaaatgc tgcactgtgc ggctaggccg 1860 gtgagtgagc ggcgcggagc caatcagcgc tcgccgttcc gaaagttgcc ttttatggct 1920 cgagtggccg ctgtggcgtc ctataaaacc cggcggcgca acgcgcagcc actgtcgagt 1980 ccgcgtccac ccgcgagcac aggcctttcg cagctctttc ttcgccgctc cacacccgcc 2040 accaggtaag cagggacaac aggcccagcc ggccacagcc ctcccgtggg cagtgaccgc 2100 gctgcagggt cgcgggggac actcggcgcg gacaccgggg aaggctggag ggtggtgccg 2160 ggccgcggag cggacacttt cagatccaac tttcagtcca gggtgtagac cctttacagc 2220 cgcattgcca cggtgtagac acçggtggac ccgctctggc tcagagcacg cggcttgggg 2280 gaacccatta gggtcgcagt gtgggcgcta tgagagccga tgcagctttc gggtgttgaa 2340 ccgtatctgc ccaccttggg gggaggacac aaggtcggga gccaaacgcc acgatcatgc 2400 cttggtggcc catgggtctt tgtctaaacc ggtttgccca tttggcttgc cgggcgggcg 2460 ggcgcggcgg gcccggctcg gccgggtggg ggctgggttg ccactgcgct tgcgcgctct 2520 atggctgggt attggggcgc gtgcacgctg gggagggagc ccttcctctt ccccctctcc 2580 caagttaaac ttgcgcgtgc gtattgagac ttggagcgcg gccaccgggg ttgggcgagg 2640 gcggggccgt tgtccggaag gggcggggtc gcagcggctt cggggcgcct gctcgcgctt 2700 cctgctgggt gtggtcgcct cccgcgcgcg cactagccgc ccgccggcgg ggcgaaggcg 2760 gggcttgcgc ccgtttgggg agggggcgga ggcctggctt cctgccgtgg ggccgcctcc 2820 ggaccagcgt ttgcctctta tggtaataac gcggccggcc tgggcttcct ttgtcccctg 2880 agtttgggcg cgcgccccct ggcggcccga ggccgcggct tgccggaagt gggcagggcg 2940 gcagcggctg cgcctagtgg cccgctagtg accgcgaccc tcttttgtgc cctgatatag 3000 ttcgccg 3007 <210>2 <211> 2493

<212> DNA <213> Rattus norvegicus <400 2 tgtgggaaag ataaagtcgc tctgaacctg ggggtgtgtt tccagtatgc tggagtggtg 60 gtcacccttt ccagactgga ggcctctgca acttcaaaat gccctgccac aagcctagaa 120 caaggaagct ggtctggcct cctcatgcac agccactgta gcccatatat ggatgaagcc 180 ttccttggtt tcaacaccta cactttgtga gccagtgcac acctactatg catgtgtaaa 240 gccatggcag gtccagagca tcccacctga agcattctcc ttgcctaaat atagctttct 300 gtcactctct cccaggagtt gtgcgtcctt ctaagctaag ctgagggacc cgaccctcaa 360 ctctgatccc ctgctgtagc tatcagccaa atggctagct tcctgagcag aactctccta 420 cttaggtgag gagagcaggg ggttcttctc tctggaggat ttggggctct ggtgaccacc 480 agcacttccc tgagtagttt gtcactccca gagtccccgt ggccagcaga tgaacagttc 540 agtgtacagt tcagctgtgg ctgcacataa tacatagagg ctagatggtg ggctccagcc 600 caacgatgcc tggcagtcac ccagagccac tagctaacgg cccaggctta gtcttgcctg 660 ggtgtgatca ggcagccctc caaaagtgcc ggactccatg agaagttttg cttgttcgat 720 tgagcacagt tcctttctag gtccggggca gaggatatct ggaggcatct tcctgcaaca 780 aacacctcca gtcactggac caccggggct tgccct,atcc ttgggactct ggccttgagt 840 ggtcaagatc cctgaagacc ttcccaacca cagctctgct tccaagttgt accccaacac 900 acctagcaaa ttagaactgc agcagaaggc ccccagatct ggctttcctg actattgcta 960 gcaaggggga gtgactctct gcccattcaa tccagacccc gtgtgtccct caaacaaaag 1020 gccactcaaa tagggtccgg gccttcaagc tgaccctcgc ccacttaggt gatcattatt 1080 cccgtgacat ccacacccag agggtcctgg ggtgggtggg tgacccccag aatacaggcc 1140 tagtaaccga gtcactgaat gggatagtgt ccacaagggc gggggctatt cttgtccatc 1200 tgggcctacg gaaccagcac ccatcgccaa actcttcatc ctcttcctca atctcgcttt 1260 ctctctcgct cgcttttttt tcttcttttt tttttttttt tttttttttt gcaaaaggag 1320 gggagagggg gtaaaaaaat gctgcactgt gcggcgaggc cggtgagtga gcgacgcgga 1380 gccaatcagc gcccgccgtt ccgaaagttg ccttttatgg ctcgagtggc cgctgtggcg 1440 tcctataaaa cccggcggcg caacgcgcag ccactgtcga gtccgcgtcc acccgcgagt 1500 acaaccttct tgcagctcct ccgtcgccgg tccacacccg ccaccaggta agcagggacg 1560 tcgggcccag cgggccccaa ctttaccttg gccactacct cgctgcagga tcgtgaggaa 1620 cactcagaag ggacaccgta gaggggtgga gcgtggtacc gggccgcgga gcggacactg 1680 gcaaagctta actttccgcc tagggtgtag agtgtttgca gtcgtattcc cgcggtgtag 1740 acactcgtgg gcacgctcct gcttggtgcg cggggcttgg ggacacacta gagtcgcggt 1800 gtgggcattt ggagagccgg tgcggcttgc gggtgttaag ccgcatctgt ccaccttgag 1860 gggacacagt attgggagtc aggcgttaca atcacgcttt gatggcctat gggtctttgt 1920 ccaaaccggt tttgcccatt cggcttggcg ggcgcggcgg ggccggctcg gccgggtggg 1980 ggctgggatg ccattgcgcg tgcgcgctct atcactgggc attggggcgc gtgcgcgctg 2040 gggagggaac tcttcctctc cccctcttcc gagttaagag ttgcgcgtgc gtattgagac 2100 taggagcgcg gccgccccgg gttgggcgag ggcggggccg ttgcccggaa ggggcggggt 2160 cgtagcggct agggcgcctg ctcgcgcttc ctgctgggtg tggtcgcctc ccgcgcgcgc 2220 actagccgcc cgtcgcctca gtgtaggcgg ggcctgtgcc cgtttgggga gggggcggag 2280 gcctggcttc ctgccgtggg tccgcctccg ggccagcgtt tgccttttat ggtaataatg 2340 cggctgtcct gcgcttcctt tgtcccctga gcttgggcgc gcgccccctg gcggctcgag 2400 gccgcggctt gccggaagtg ggcagggcgg cagcggctgc tcttggcggc tccgcggtga 2460 ccatagccct cttttgtgcc ttgatagttc gcc 2493 <210> 3 <211 >2953

<212> DNA <213> Mus musculus <400>3 agaccagaat tgtttcagag gtcgggtggg gctgaggtgc ctgccccttg accagtccca 60 ggactgagag gtgacaaagt ggcaacacag gtcctgcctg ggaatctggt ctgctctaac 120 ctagtaaagc tgtctggtgt cacccaagag gctccctcca catcctgcac ccctgatggc 180 tgatggcatc tttctccctt gcaccccacc agggttctcc tgggaatact ctgggctctc 240 cttattgaca ggcagcattt gccctgcccc acccccacct gtgacttgca ggactggcag 300 gtccttgggc agctggcaaa ctgcctgagc aactgagaaa tacaaggcca gggccagggc 360 agtcctgtcc cccggaggca gggaggagac tgcctgggaa agttctctca gggttggtga 420 ctgcagaaga cttttgtcaa attttttttt tttttttggt gggaaagata actaggggtg 480 tgtttccagt tcacagcata tgctggggtg atggtcacct cttccagaca aggcctcagc 540 aacttcaaaa tgccctgcca ccagccaaga acaaggaagc tggccactgt agtccatata 600 tggatgaagc cttctttggt ttcaacacct acactttgtg agccagtgaa cacctaccta 660 tgcatgcact gaggcacggc aggcccagag catctcacct gaagcaccct tcttgcctaa 720 atccagcttt ctgtcacact ctcccagaag gtgcgtgtcc ttctaagcta agctgaggga 780 tccggccctc aaccctgacc ccgtgtgtag ctctcagcca aatagctggc ttgctaagta 840 gaacactggt acttaggtga gggggacagg ggctgcttct ctctggagga tttggggctc 900 cggtgaccac caacttttcc ctgagcagct tgtcactccc agaatcccca cggctggcag 960 atggactagt gcacaactca gctgtggctg cacataataa atagaggata gatggtgggc 1020 cccagcccag cgatgtctgg cagtcaccca gagacactag ctaacggccc aggcttagtc 1080 ttgcctgggt gtgatcaggc agttctccaa aagtgcctga ctccatgaga agttttgttt 1140 gttctattga gcacagttcc tttctagatc cggggcaggg gatatctgga ggcatcttct 1200 tgcaacacct ccagttattg gaccactggg gctcgcccta tgcttgggat aggatggcct 1260 tgagtctcta agaggtcaag atccatgaaa acctctccaa ccagagttct gcttccaagt 1320 tgaaccccaa cacacctagc aaattagaac cacagcagaa ggggcccccc cggatctggc 1380 tttccggcta ttgctagcaa ttgctagcaa gggggagtga ctctctgtcc attcaatcca 1440 ggccccgcgt gtccctcaaa caagaggcca cacaaatagg gtccgggcct cgatgctgac 1500 cctcatccac ttaagtgctc gatatccacg tgacatccac acccagaggg tcctggggtg 1560 gttgggtgac ccccagaatg caggcctagt aaccgagaca ttgaatgggg cagtgtccac 1620 aagggcggag gctattcctg tacatctggg cctacggagc cagcacccat cgccaaaact 1680 cttcatcctc ttcctcaatc tcgctttctc tctcgctttt tttttttttc ttcttctttt 1740 tttttttttt tttcaaaagg aggggagagg gggtaaaaaa atgctgcact gtgcggcgag 1800 gccggtgagt gagcgacgcg gagccaatca gcgcccgccg ttccgaaagt tgccttttat i860 ggctcgagtg gccgctgtgg cgtcctataa aacccggcgg cgcaacgcgc agccactgtc 1920 gagtcgcgtc cacccgcgag cacagcttct ttgcagctcc ttcgttgccg gtccacaccc 1980 gccaccaggt aagcagggac gccgggccca gcgggccttc gctctctcgt ggctagtacc 2040 tcactgcagg gtcctgagga tcactcagaa cggacaccat gggcgggtgg agggtggtgc 2100 cgggccgcgg agcggacact ggcacagcca áctttacgcc tagcgtgtag actctttgca 2160 gccacattcc cgcggtgtag acactcgtgg gcccgctccc gctcggtgcg tggggcttgg 2220 ggacacacta gggtcgcggt gtgggcattt gatgagccgg tgcggcttgc gggtgttaaa 2280 agccgtatta ggtccatctt gagagtacac agtattggga accagacgct acgatcacgc 2340 ctcaatggcc tctgggtctt tgtccaaacc ggtttgccta ttcggcttgc cgggcgggcg 2400 ggcgggcggg cgggcgcggc agggccggct cggccgggtg ggggctggga tgccactgcg 2460 cgtgcgctct ctatcactgg gcatcgaggc gcgtgtgcgc tagggaggga gctcttcctc 2520 tccccctctt cctagttagc tgcgcgtgcg tattgaggct gggagcgcgg ctgcccgggg 2580 ttgggcgagg gcggggccgt tgtccggaag gggcggggtc acagtggcac gggcgccttg 2640 tttgcgcttc ctgctgggtg tggtcgcctc ccgcgcgcgc acaagccgcc cgtcggcgca 2700 gtgtaggcgg agcttgcgcc cgtttgggga gggggcggag gtctggçttc ctgccctagg 2760 tccgcctccg ggccagcgtt tgccttttat ggtaataatg cggccggtct gcgcttcctt 2820 tgtcccctga gcttgggcgc gcgccccctg gcggctcgag cccgcggett gccggaagtg 2880 ggcagggcgg cagcggctgc tcttggcggc cccgaggtga ctatagcctt cttttgtgtc 2940 ttgatagttc gcc 2953

<210>4 <211> 4164 <212> DNA <213> Cricetulus griseus <400>4 aatgctgcac tgtgcggcta ggccggtgag tgagcggcgc ggagccaatc agcgctcgcc 60 gttccgaaag ttgcctttta tggctcgagt ggccgctgtg gcgtcctata aaacccggcg 120 gcgcaacgcg cagccactgt cgagtccgcg tccacccgcg agcacaggcc tttcgcagct 180 ctttcttcgc cgctccacac ccgccaccag gtaagcaggg acaacaggcc cagccggcca 240 cagccctccc gtgggcagtg accgcgctgc agggtcgcgg gggacactcg gcgcggacac 300 cggggaaggc tggagggtgg tgccgggccg cggagcggac actttcagat ccaactttca 360 gtccagggtg tagacccttt acagccgcat tgccacggtg tagacaccgg tggacccgct 420 ctggctcaga gcacgcggct tgggggaacc cattagggtc gcagtgtggg cgctatgaga 480 gccgatgcag ctttcgggtg ttgaaccgta tctgcccacc ttggggggag gacacaaggt 540 cgggagccaa acgccacgat catgccttgg tggcccatgg gtctttgtct aaaccggttt 600 gcccatttgg cttgccgggc gggcgggcgc ggcgggcccg gctcggccgg gtgggggctg 660 ggttgccact gcgcttgcgc gctctatggc tgggtattgg ggcgcgtgca cgctggggag 720 ggagcccttc ctcttccccc tctcccaagt taaacttgcg cgtgcgtatt gagacttgga 780 gcgcggccac cggggttggg cgagggcggg gccgttgtcc ggaaggggcg gggtcgcaga 840 ggattcgggg cgcctgctcg cgcttcctgc tgggtgtggt cgcctcccgc gcgcgcacta 900 gaccgcccgg cgggggggcg aaggcgggtc ttgcgcccgt ttggggaggg ggcggagacc 960 tggcttcctg ccgtggggcc gcctccggac cagcgttrgc ctcttatggt aataacgcgg 1020 ccggcctggg cttcatttgt cccctgagtt tgggcgcgcg ccccctggcg gcccgagacc 1080 gcggcttgcc ggaagtgggc agggcggcaa cggctgcgcc tagtggcccg ccagtgaccg 1140 cgaccctctt ttgtgccctg atatagttcg ccatggatga cgatatcgct gcgctcgttg 1200 tcgacaacgg ctccggcatg tgcaaagccg gcttcgcggg cgacgatgct ccccgggccg 1260 tcttcccatc catcgtgggc cgccctaggc accaggtagg tgacccttcc ctttgcgggt 1320 agcgatgctg gggttttcct ggggggagag gtgaccatat tgagaacatc gttcccctcc 1380 gcagggcgtg atggtgggca tgggccagaa ggactcctac gtgggtgacg aggcccagag 1440 caagagaggt attctgaccc tgaagtaccc cattgaacac ggcattgtca ccaactggga 1500 cgatatggag aagatctggc accacacctt ctacaacgag ctgcgtgtgg cccccgagga 1560 gcaccctgtg ctgctcaccg aggcccccct gaaccccaag gccaaccgtg aaaagatgac 1620 ceaggtcagc agccagggtg gccacctcca tctttgccaa cttctcggcc acgccctttc 1680 tcaattgtct ttcttctgcc gttctcccat aggactctct tctatgagct gagtctccct 1740 tggaactttg cagtttctgc tttttccccg atgaggtcct ttttttctct tgattgcctt 1800 tctgactagg tgttttaaac cctacggtgc tgtgggtgta ggtactaaca atgactcgtg 1860 tgacaaacct aatgaggctg gtgataagtg gccttggagt gtgtattcag tagatgcaca 1920 gtaggtttaa aatggagccc ctgtcctgag atttctccca gcacacttac cttagctgtg 1980 ttcttgcact ctgcatgtcc catatctgtc ctgacagtcc tacctgcctt gactacttgt 2040 ggcttttgga gtttgacaat gcctcatttt tctttataga tcatgtttga gaccttcaac 2100 accccagcca tgtacgtagc cattcaggct gtgctgtccc tgtatgcctc tggtcgtacc 2160 actggcattg tgatggactc cggagacggg gtcacccaca ctgtgcccat ctatgagggc 2220 tacgctctcc ctcatgccat cctgcgtctg gacctggctg gccgggacct gacagactac 2280 ctcatgaaga tcctgaccga gcgtggctac agctttacca ccacagctga gagggaaatt 2340 gtgcgtgaca tcaaagagaa gctgtgctat gttgccctgg acttcgagca ggagatggcc 2400 actgctgcat cctcttcctc cctggagaag agctatgagc tgcctgatgg ccaggtcatc 2460 accattggca atgagcggtt ccgttgccct gaggctcttt tccagccttc cttcctgggt 2520 gagttgaagt gacctagttt cttcatctaa tggtgaccaa ctcttgatct tgagaccatg 2580 ctataagtct atctttctct ttcccttttc cctcaggtat ggaatcctgt ggcatccacg 2640 aaactacatt caattccatc atgaagtgtg acgtcgacat ccgcaaagac ctctatgcca 2700 acacagtgct gtctggtggt accaccatgt acccaggcat tgctgaccgg atgcagaagg 2760 agatcactgc tctggctccc agcaccatga agatcaaggt gagctaagca tccttagcct 2820 tggacccatg atgggccctt ccaggtcaac cccttgactg tgggtaagac aggagtccag 2880 agcactcact atcactgtgt cttggcttct cagatcattg ctcctcctga gcgcaagtac 2940 tctgtgtgga tcggtggctc catcctggcc tcactgtcca ccttccagga gatgtggatc 3000 agcaagcagg agtacgatga gtccggcccc tccatcgtcc accgcaaatg cttctaggcg 3060 gactgttact gagctgtgtt ttacaccctt tctttgacaa aacctaactt gcgcagaaaa 3120 aaaaatgaga caacattggc atggctttgt ttttttgttt tgttttttta atttttttaa 3180 aaaaggtttt gttttttttt ttttttgtgt tgttttggcg cttttgactc aggatttaaa 3240 aactggaacg gtgaaggcga cagcagtcgg ttggagcaaa catcccccaa agttctacaa 3300 tgtggctgag gactttgatt gcacattttt tttctttttt aagtcattcc aagtacccat 3360 gagatggcta caggaagtcc ctcaccctcc caaaagccat ccccattccc tagaagagga 3420 tggctgagtc cattccctga gtccacaccg gggaggtgac agcattgctt ctgtgtaaat 3480 tatggactcc caaaattttt ttaaatcttc cgccttaaaa cttcttttgt ttttaatttt 3540 ggatggtcaa ccatcgtggc cccttttttt tttttttttt tttgtccccc caacttgatg 3600 tatgaaggct tttggtctcc ctgggagtgg gttgaggtgt tgaggcagcc agggcttgcc 3660 tgtacactga cttgagacca gtttaataaa gtgcacacct tacaaacagt gctgcttgtt 3720 tgtggctttg ctagattctg ggtagcagcg ggggaggggg tcactattac ctttgctcca 3780 agaggttcta gggtggtctg ggccttgcct agtagttttt agtgggagga cacaagcatc 3840 atgaccttta accagttatc acaaataccc tgtccattga gttctgaagt cttaattgtg 3900 tcttggttgg aagggtgtcc atcctgaatt gggaataccc cctgggccaa gttgggttcc 3960 tgcagcaaac aaccctgtaa tctcaacctt cctctacctt tgtgggaagc aggaatcctg 4020 ttgggagggt agctttactg cctttgagtt ctgcaagaca gtgggaagta aaagcagtct 4080 cggttctctt gctttaccag atacatgatc acaaagttta agggtgttaa ggctccccag 4140 gcatgggtat ctttccccgg tacc 4164 <210> 5 <211 >2011

<212> DNA <213> Homo sapiens <400>5 gagctctgtc tcttggccag ctgaatggag gcccagcggc aacacaggtc ctgcctgggg 60 atcaggtctg ctctgcaccc caccttgctg cctggagccg cccacctgac aacctctcat 120 ccctgctctg tagatccggt cccatcccca ctgcccaccc caccccccca gcactccacc 180 cagttcaacg ttccacgaac ccccagaacc agccctcatc aacaggcagc aagaagggcc 240 ccccgcccat cgccccacaa cgccagccgg gtgaactgta gcgttggcag gtcctgaggc 300 agctgaaaga tacaaggcca gggacaggac agtcccatcc ccaggaggca gggagtatac 360 aggctgggga agtttgccct tgcgtggggt ggtgatggag gaggctcagc aagtcttctg 420 gactgtgaac ctgtgtctgc cactgtgtgc tgggtggtgg tcatctttcc caccaggctg 480 tggcctctgc aaccttcaag ggaggagcag gtcccattgg ctgagcacag ccttgtacgt 540 gaactgaaca agcagcctcc ttcctggcca caggttccat gtccttatat ggactcatct 600 ttgcctattg cgacacacac tcaatgaaca cctactacgc gctgcaaaga gccccgcagg 660 cctgaggtgc ccccacctca ccactcttcc tatttttgtg taaaaatcca gcttcttgtc 720 accacctcca aggaggggga ggaggaggaa ggcaggttcc tctaggctga gccgaatgcc 780 cctctgtggt cccacgccac tgatcgctgc atgcccacca cctgggtaca cacagtctgt 840 gattcccgga gcagaacgga ccctgcccac ccggtcttgt gtgctactca gtggacagac 900 ccaaggcaag aaagggtgac aaggacaggg tcttcccagg ctggctttga gttcctagca 960 ccgccccgcc cccaatcctc tgtggcacat ggagtcttgg tccccagagt cccccagcgg 1020 cctccagatg gtctgggagg gcagttcagc tgtggctgcg catagcagac atacaacgga 1080 cggtgggccc agacccaggc tgtgtagacc cagccccccc gccccgcagt gcctaggtca 1140 cccactaacg ccccaggcct ggtcttggct gggcgtgact gttaccctca aaagcaggca 1200 gctccagggt aaaaggtgcc ctgccctgta gagcccactt ccttcccagg gctgcggctg 1260 ggtaggtttg tagccttcat cacgggccac ctccagccac tggaccgctg gcccctgccc 1320 tgtcctgggg agtgtggtcc tgcgactcta atggccgcaa gccacctgac tcccccaaca 1380 ccacactcta cctctcaagc ccaggtctct ccctagtgac ccacccagca catttagcta 1440 gctgagcccc acagccagag gtcctcaggc cctgctttca gggcagttgc tctgaagtcg 1500 gcaaggggga gtgactgcct ggccactcca tgccctccaa gagctccttc tgcaggagcg 1560 tacagaaccc agggccctgg cacccgtgca gaccctggcc caccccacct gggcgctcag 1620 tgcccaagag atgtccacac ctaggatgtc ccgcggtggg tggggggccc gagagacggg 1680 caggccgggg gcaggcctgg ccatgcgggg ccgaaccggg cactgcccag cgtggggcgc 1740 gggggccacg gcgcgcgccc ccagcccccg ggcccagcac cccaaggcgg ccàacgccaa 1800 aactctccct cctcctcttc ctcaatctcg ctctcgctct tttttttttt cgcaaaagga 1860 ggggagaggg ggtaaaaaaa tgctgcactg tcggcgaagc cggtgagtga gcggcgcggg 1920 gccaatcgcg tgcgccgttc cgaaagttgc cttttatggc tcgagcggcc gcggcggcgc 1980 cctataaaac ccagcggcgc gacgcgccac c 2011 <210 6 <211>1278 <212> DNA <213> Gallus gallus <400 6 tcgaggtgag ccccacgttc tgcttcactc tccccatctc ccccccctcc ccacccccaa 60 ttttgtattt atttattttt taattatttt gtgcagcgat gggggcgggg gggggggggg 120 cgcgcgccag gcggggcggg gcggggcgag gggcggggcg gggcgaggcg gagaggtgcg 180 gcggcagcca atcagagcgg cgcgctccga aagtttcctt ttatggcgag gcggcggcgg 240 cggcggccct ataaaaagcg aagcgcgcgg cgggcgggag tcgctgcgtt gccttcgccc 300 cgtgccccgc tccgcgccgc ctcgcgccgc ccgccccggc tctgactgac cgcgttactc 360 ccacaggtga gcgggcggga cggcccttct cctccgggct gtaattagcg cttggtttaa 420 tgacggctcg tttcttttct gtggctgcgt gaaagcctta aagggctccg ggagggccct 480 ttgtgcgggg gggagcggct cggggggtgc gtgcgtgtgt gtgtgcgtgg ggagcgccgc 540 gtgcggcccg cgctgcccgg cggctgtgag cgctgcgggc gcggcgcggg gctttgtgcg 600 ctccgcgtgt gcgcgagggg agcgcggccg ggggcggtgc cccgcggtgc gggggggctg 660 cgaggggaac aaaggctgcg tgcggggtgt gtgcgtgggg gggtgagcag ggggtgtggg 720 cgcggcggtc gggctgtaac ccccccctgc acccccctcc ccgagttgct gagcacggcc 780 cggcttcggg tgcggggctc cgtgcggggc gtggcgcggg gctcgccgtg ccgggcgggg 840 ggtggcggca ggtgggggtg ccgggcgggg cggggccgcc tcgggccggg gagggctcgg 900 gggaggggcg cggcggcccc ggagcgccgg cggctgtcga ggcgcggcga gccgcagcca 960 ttgcctttta tggtaatcgt gcgagagggc gcagggactt cctttgtccc aaatctggcg 1020 gagccgaaat ctgggaggcg ccgccgcacc ccctctagcg ggcgcgggcg aagcggtgcg 1080 gcgccggcag gaaggaaatg ggcggggagg gccttcgtgc gtcgccgcgc cgccgtcccc 1140 ttctccatct ccagcctcgg ggctgccgca gggggacggc tgccttcggg ggggacgggg 1200 cagggcgggg ttcggcttct ggcgtgtgac cggcggggtt tatatcttcc cttctctgtt 1260 cctccgcagc cagccatg 1278

<210> 7 <211> 3668 <212> DNA <213> Artificial Sequence <220> <223> longer beta-actin promoter sequence from CHO cells <400>7 cttcctccac ttcctcttcc cccaccccca ccctgttttc tgtgctctct cctgtctgca 60 catcaaactc aacaactcag gcatccccct ctggccctgc catcttctca gggtcçtctc 120 cttcttcatg gctgaggaca cccaggccag gcagcctcgt attcatccaa cagaacagag 180 cccctcàgtg tgtgtgtagt gggaggaagt gggggtgttg gagcccctca aagggctgtc 240 ttgtttgatg ttgtgggggt tgggggcagt gctgagttaa gactagcctg aatagcacca 300 tgactgtctg catagctact caggaagctg aggcaggaag atgaggagtt ggaggccagc 360 ctgggctata tagggagaca ctatttcaaa caaacaggag gagctgggca tggtggcata 420 tgcctttaat cataacactc aggaagtaca ggcaggagga ttaggagttc aaggttactt 480 gggctacata gagaatttga ggccagtcta ggctgcgtga gacactgtca aaaaaacaaa 540 agaacaaaac ccccacacac aaaaaaaact tcccaacaaa ccaagaaaat caatctctct 600 ctcgttatct cttgctttct ctcatgccta agagaacact ggaaaatggc cattgcagac 66Ó cgggaccaag acagaaccat aagccagtgg gatagatcag aaatgttcca gaggtgggat 720 ggggccagag tgcctgcccc ttgaaccgtc ccagggacca gaggtgacaa agtggcaaca 780 caggtcctgc ctgggaatct ggtctgctcc tacttagtaa agctgcctgg tgtcacacaa 840 gaggccccca cttattcctg cacccctggt ggtaggtggc gtcttctccc ctgcagccac 900 caggctcccc tgagaacact gccggcagtc ctcattgaca ggcagtattc gctctgcccc 960 acccccacct gtgaattgca gggctggcag gtcctcaggc agctggcaaa ccgcctgaac 1020 aactgagaga tacagggcca gggccagggc agtcccgtcc cccggaggca gggaggggac 1080 gtgctgggaa agttctctct ctcaggccca ggttggtgac tgcagaággc ttctgtcaaa 1140 tctcttttgt gggaaccaca gagtagccct gaacgtgggg gtgtgcttcc agtatactct 1200 ggggtcaccc tttccatact ggaggcctct gcaacttcaa aatgctctgc taccaaccta 1260 gcacaaggaa gttggtccag cctccccacg cagggccact gctgcagtcc atatatggac 1320 taagccttcc ttggtttcaa cacctacact cactgagccc ctactatgtg tatgcagagc 1380 cgagacaggc ccgagcatct catctgaagc acccttcttg cctaaattca gttttctgtc 1440 actttctccc aggaggtgtg tgtccctcta agctaagcca ggggtccctc acccctgccc 1500 cactcccatc cctagtgtag gtatcagctg aagagcttcc tgagcagaac actcttgggt 1560 gctgacattt tgataaatag gcccatgttt aggagagcag gggtccgggg gcgggagatc 1620 ttctctggtg gattgagggc tccaagaact actctttgag cacgctgccc ctcccagagt 1680 ccccacagcc tccagatgga ctagaacaca gttcggctgt ggctgcacat aactaacaga 1740 ggatagatgg tgggtcccag cccaacagtg cctggcaatc acccagagcc accagctaac 1800 ggccttggct tagttttttg cctgggtgtg atcaggcagc cctccaaaac tgcccggact 1860 ccatgacaag ttttgcttgt tctatagagc acagttcctt tctaggtctg gggcaaggga 1920 catcgggaga catcttcctg caacagctcc agtcactgga ccaccaggct cgccctgtct 1980 ttggtgtgtg gccctgagtc tcctaagtgg cccaaacctg tgaagacccc tccaaccaca 2040 gttttgcttc taaattgtac cccaacacac ctagcaaatt gaaa'ccccac cagaagtccc 2100 ccagatctgg ctttccggct attgctggca agggggagtg actcccggcc cattcaatcc 2160 aggccccgcg tgttcctcaa acaagaagcc acgtaaacat aaaccgagcc tccatgctga 2220 cccttgccca tcgaggtact caatgttcac gtgatatcca cacccagagg gtcctggggt 2280 gggtgcatga gccccagaat gcaggcttga taaccgagac cctgaatcgg gcagtgtcca 2340 caagggcgga ggcccagtca tgcatgttcg ggcctatggg gccagcaccc aacgccaaaa 2400 ctctccatcc tcttcctcaa tctcggcttt ctctctctct ctcttttttt ttttttattt 2460 tttttttttg caaaaggagg ggagaggggg taaaaaaatg ctgcactgtg cggctaggcc 2520 ggtgagtgag cggcgcggag ccaatcagcg ctcgccgttc cgaaagttgc cttttatggc 2580 tcgagtggcc gctgtggcgt cctataaaac ccggcggcgc aacgcgcagc cactgtcgag 2640 tccgcgtcca cccgcgagca caggcctttc gcagctcttt cttcgccgct ccacacccgc 2700 caccaggtaa gcagggacaa caggcccagc cggccacagc cctcccgtgg gcagtgaccg 2760 cgctgcaggg tcgcggggga cactcggcgc ggacaccggg gaaggctgga gggtggtgcc 2820 gggccgcgga gcggacactt tcagatccaa ctttcagtcc agggtgtaga ccctttacag 2880 ccgcattgcc acggtgtaga caccggtgga cccgctctgg ctcagagcac gcggcttggg 2940 ggaacccatt agggtcgcag tgtgggcgct atgagagccg atgcagcttt cgggtgttga 3000 accgtatctg cccaccttgg ggggaggaca caaggtcggg agccaaacgc cacgatcatg 3060 ccttggtggc ccatgggtct ttgtctaaac cggtttgccc atttggcttg ccgggcgggc 3120 gggcgcggcg ggcccggctc ggccgggtgg gggctgggtt gccactgcgc ttgcgcgctc 3180 tatggctggg tattggggcg cgtgcacgct ggggagggag cccttcctct tccccctctc 3240 ccaagttaaa cttgcgcgtg cgtattgaga cttggagcgc ggccaccggg gttgggcgag 3300 ggcggggccg ttgtccggaa ggggcggggt cgcagcggct tcggggcgcc tgctcgcgct 3360 tcctgctggg tgtggtcgcc tcccgcgcgc gcactagccg cccgccggcg gggcgaaggc 3420 ggggcttgcg cccgtttggg gagggggcgg aggcctggct tcctgccgtg gggccgcctc 3480 cggaccagcg tttgcctctt atggtaataa cgcggccggc ctgggcttcc tttgtcccct 3540 gagtttgggc gcgcgccccc tggcggcccg aggccgcggc ttgccggaag tgggcagggc 3600 ggcagcggct gcgcctagtg gcccgctagt gaccgcgacc ctcttttgtg ccctgatata 3660 gttcgccg 3668

<210> 8 <211 > 19 <212> DNA <213> Artificial Sequence <220> <223> forward primer for beta-actin <400 8 gctctttctt cgccgctcc 19

<210 9 <211 > 19 <212> DNA <213> Artificial Sequence <220> <223> reverse primer for beta-actin <400> 9 a cca ccctcc ag ccttccc 19

<210> 10 <211 >20 <212> DNA <213> Artificial Sequence <220> <223> forward primer for EF-1 <400> 10 gaacgcaggt gttgtgaaaa 20

<210> 11 <211 > 17 <212> DNA <213> Artificial sequence <220> <223> reverse primer for EF-1 <400> 11 ctcggcagcc tccttct 17

<210 12 <211 > 16 <212> DNA <213> Artificial Sequence <220 <223> forward primer for rps21 <400 12 gtggacctgt acgtgc 16

<210> 13 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> reverse primer for rpS21 <400> 13 ttctcacttt tatttatgac 20

<210> 14 <211>21 <212> DNA <213> Artificial Sequence <220> <223> forward primer for ferritin <400> 14 cgccagaact accaccagga c 21

<210> 15 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> reverse primer for ferritin <400> 15 ttcagagcca catcatcccg 20

<210> 16 <211>21 <212> DNA <213> Artificial Sequence <220> <223> forward primer for galectin <400> 16 tggtcgcaag caacctgaat c 21

<210> 17 <211> 20 <212> DNA <213> Artificial Sequence <220 <223> reverse primer for galectin <400 17 ttgaagtcac cgtctgccgc 20

<210> 18 <211 > 17 <212> DNA <213> Artificial Sequence <220> <223> forward M13 primer <400> 18 gttttcccag tcacgac 17

<210> 19 <211 > 14 <212> DNA <213> Artificial Sequence <220> <223> alu repeat SAGE tag <400> 19 catggaagca gaat 14

<210> 20 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Mitochondrial cox I SAGE tag <400> 20 catgcaggag cttc 14

<210> 21 <211> 14 <212> DNA <213> Artificial sequence <220> <223> Ribosomal Protein S21 SAGE tag <400> 21 catgggggag cgtt 14

<210> 22 <211> 14 <212> DNA <213> Artificial sequence <220> <223> Mitochondrial COX II SAGE tag <400 22 catggtactg acac 14

<210> 23 <211 > 14 <212> DNA <213> Artificial sequence <220> <223> GAPDH SAGE tag <400> 23 catggcctcc aagg 14

<210> 24 <211 > 14 <212> DNA <213> Artificial Sequence <220> <223> Mitochondrial ATPase SAGE tag <400> 24 catgataata cgta 14

<210> 25 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> B-1 repeat SAGE tag <400> 25 catgccttta atcc 14

<210> 26 <211> 14 <212> DNA <213> Artificial sequence <220> <223> Mitochondrial cytochrome B SAGE tag <400> 26 catgaatcgg aggc 14

<210> 27 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> EF-1 SAGE tag <400> 27 catgaggcag acag 14

<210> 28 <211 > 14 <212> DNA <213> Artificial sequence <220 <223> Galectin SAGE tag <400 28 catggcggca gacg 14

<210> 29 <211 > 14 <212> DNA <213> Artificial sequence <220> <223> Alu repeat SAGE tag <400> 29 catggtggct caca 14

<210> 30 <211 > 14 <212> DNA <213> Artificial sequence <220> <223> Ferritin heavy chain SAGE tag <400> 30 catgttggct gccg 14

<210> 31 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> unknown SAGE tag <400> 31 catgccctgt gccg 14

<210> 32 <211> 14 <212> DNA <213> Artificial sequence <220> <223> Ribosomal protein L41 SAGE tag <400> 32 catgagagcg aagt 14 <210> 33

<211 > 14 <212> DNA <213> Artificial sequence <220 <223> Mitochondrial Dehydrogenase SAGE tag <400 33 catgaggagg ccta 14

<210> 34 <211 > 14 <212> DNA <213> Artificial Sequence <220> <223> beta-actin SAGE tag <400> 34 catgccctga gtcc 14

<210> 35 <211> 26 <212> DNA <213> Artificial Sequence <220> <223> forward primer for amplifying beta-actin promoter containing intron 1 <400> 35 aggcccagct tgggaccaag acagaa 26

<210> 36 <211> 27 <212> DNA <213> Artificial Sequence <220 <223> reverse primer for amplifying beta-actin promoter containing intron 1. <400> 36 cgcggatccg gcgaactata tcagggc 27

<210> 37 <211> 1884 <212> DNA <213> Artificial Sequence <220> <223> cDNA enoding acid-sphingomyelinase <400> 37 atggcccgct acggagcgtc actccgccag agctgcccca ggtccggccg ggagcaggga 60 caagacggga ccgccggagc ccccggactc ctttggatgg gcctggcgct ggcgctggcg 120 ctggcgctgg ctctgtctga ctctcgggtt ctctgggctc cggcagaggc tcaccctctt 180 tctccccaag gccatcctgc caggttacat cgcatagtgc cccggctccg agatgtcttt 240 gggtggggga acctcacctg cccaatctgc aaaggtctat tcaccgccat caacctcggg 300 ctgaagaagg aacccaatgt ggctcgcgtg ggctccgtgg ccatcaagct gtgcaatctg 360 ctgaagatag caccacctgc cgtgtgccaa tccattgtcc acctctttga ggatgacatg 420 gtggaggtgt ggagacgctc agtgctgagc ccatctgagg cctgtggcct gctcctgggc 480 tccacctgtg ggcactggga cattttctca tcttggaaca tctctttgcc tactgtgccg 540 aagccgcccc ccaaaccccc tagcccccca gccccággtg cccctgtcag ccgcatcctc 600 ttcctcactg acctgcactg ggatcatgac tacctggagg gcacggaccc tgactgtgca 660 gacccactgt gctgccgccg gggttctggc ctgccgcccg catcccggcc aggtgccgga 720 tactggggcg aatacagcaa gtgtgacctg cccctgagga ccctggagag cctgttgagt 780

I gggctgggcc, cagccggccc ttttgatatg gtgtactgga çaggagacat ccccgcacat 840 gatgtctggc accagactcg tcaggaccaa ctgcgggccc tgaccaccgt cacagcactt 900 gtgaggaagt tcctggggcc agtgccagtg taccctgctg tgggtaacca tgaaagcaca 960 cctgtcaata gcttccctcc ccccttcatt gagggcaacc actcctcccg ctggctctat 1020 gaagcgatgg ccaaggcttg ggagccctgg ctgcctgccg aagccctgcg caccctcaga 1080 attggggggt tctatgctct ttccccatac cccggtctcc gcctcatctc tctcaatatg 1140 aatttttgtt cccgtgagaa cttctggctc ttgatcaact ccacggatcc cgcaggacag 1200 ctccagtggc tggtggggga gcttcaggct gctgaggatc gaggagacaa agtgcatata 1260 attggccaca ttcccccagg gcactgtctg aagagctgga gctggaatta ttaccgaatt 1320 gtagccaggt atgagaacac cctggctgct cagttctttg gccacactca tgtggatgaa 1380 tttgaggtct tctatgatga agagactctg agccggccgc tggctgtagc cttcctggca 1440 cccagtgcaa ctacctacat cggccttaat cctggttacc gtgtgtacca aatagatgga 1500 aactactccg ggagctctca cgtggtcctg gaccatgaga cctacatcct gaatctgacc 1560 caggcaaaca taccgggagc cataccgcac tggcagcttc tctacagggc tcgagaaacc 1620 tatgggctgc ccaacacact gcctaccgcc tggcacaacc tggtatatcg catgcggggc 1680 gacatgcaac ttttccagac cttctggttt ctctaccata agggccaccc accctcggag 1740 ccctgtggca cgccctgccg tctggctact ctttgtgccc agctctctgc ccgtgctgac 1800 agccctgctc tgtgccgcca cctgatgcca gatgggagcc tcccagaggc. ccagagcctg 1860 tggccaaggc cactgttttg ctga 1884

<210> 38 <211 >2859 <212> DNA <213> Artificial sequence <220 <223> cDNA encoding alpha-glucosidase. <400 38 atgggagtga ggcacccgcc ctgctcccac cggctcctgg ccgtctgcgc cctcgtgtcc 60 ttggcaaccg ctgcactcct ggggcacatc ctactccatg atttcctgct ggttccccga 120 gagctgagtg gctcctcccc agtcctggag gagactcacc cagctcacca gcagggagcc 180 agcagaccag ggccccggga tgcccaggca caccccggcc gtcccagagc agtgcccaca 240 cagtgcgacg tcccccccaa cagccgcttc gattgcgccc ctgacaaggc catcacccag 300 gaacagtgcg aggcccgcgg ctgctgctac atccctgcaa agcaggggct gcagggagcc 360 cagatggggc agccctggtg cttcttccca cccagctacc ccagctacaa gctggagaac 420 ctgagctcct ctgaaatggg ctacacggcc accctgaccc gtaccacccc caccttcttc 480 cccaaggaca tcctgaccct gcggctggac gtgatgatgg agactgagaa ccgcctccac 540 ttcacgatca aagatccagc taacaggcgc tacgaggtgc ccttggagac cccgcgtgtc 600 cacagccggg caccgtcccc actctacagc gtggagttct ctgaggagcc cttcggggtg 660 atcgtgcacc ggcagctgga cggccgcgtg ctgctgaaca cgacggtggc gcccctgttc 720 tttgcggacc agttccttca gctgtccacc tcgctgccct cgcagtatat cacaggcctc 780 gccgagcacc tcagtcccct gatgctcagc accagctgga ccaggatcac cctgtggaac 840 cgggaccttg cgcccacgcc cggtgcgaac ctctacgggt ctcacccttt ctacctggcg 900 ctggaggacg gcgggtcggc acacggggtg ttcctgctaa acagcaatgc catggatgtg 960 gtcctgcagc cgagccctgc ccttagctgg aggtcgacag gtgggatcct ggatgtctac 1020 atcttcctgg gcccagagcc caagagcgtg gtgcagcagt acctggacgt tgtgggatac 1080 ccgttcatgc cgccatactg gggcctgggc ttccacctgt gccgctgggg ctactcctcc 1140 accgctatca cccgccaggt ggtggagaac atgaccaggg cccacttccc cctggacgtc 1200 caatggaacg acctggacta catggactcc cggagggact tcacgttcaa caaggatggc 1260 ttccgggact tcccggccat ggtgcaggag ctgcaccagg gcggccggcg ctacatgatg 1320 atcgtggatc ctgccatcag cagctcgggc cctgccggga gctacaggcc ctacgacgag 1380 ggtctgcgga ggggggtttt catcaccaac gagaccggcc agccgctgat tgggaaggta 1440 tggcccgggt ccactgcctt ccccgacttc accaacccca cagccctggc ctggtgggag 1500 gacatggtgg ctgagttcca tgaccaggtg cccttcgacg gcatgtggat tgacatgaac 1560 gagccttcca acttcatcag gggctctgag gacggctgcc ccaacaatga gctggagaac 1620 ccaccctacg tgcctggggt ggttgggggg accctccagg cggccaecat ctgtgcctcc 1680 agccaccagt ttctctccac acactacaac ctgcacaacc tctacggcct gaccgaagcc 1740 atcgcctccc acagggcgct ggtgaaggct cgggggacac gcccatttgt gatctcccgc 1800 tcgacctttg ctggccacgg ccgatacgcc ggccactgga cgggggacgt gtggagctcc 1860 tgggagcagc tcgcctcctc cgtgccagaa atcctgcagt ttaacctgct gggggtgcct 1920 ctggtcgggg ccgacgtctg cggcttcctg ggcaacacct cagaggagct gtgtgtgcgc 1980 tggacccagc tgggggcctt ctaccccttc atgcggaacc acaacagcct gctcagtctg 2040 ccccaggagc cgtacagctt cagcgagccg gcccagcagg ccatgaggaa ggccctcacc 2100 ctgcgctacg cactcctccc ccacctctac acgctgttcc accaggccca cgtcgcgggg 2160 gagaccgtgg cccggcccct cttcctggag ttccccaagg actctagcac ctggactgtg 2220 gaccaccagc tcctgtgggg ggaggccctg ctcatcaccc cagtgctcca ggccgggaag 2280 gccgaagtga ctggctactt ccccttgggc acatggtacg acctgcagac ggtgccaata 2340 gaggcccttg gcagcctccc acccccacct gcagctcccc gtgagccagc catccacagc 2400 gaggggcagt gggtgacgct gccggccccc ctggacacca tcaacgtcca cctccgggct 2460 gggtacatca tccccctgca gggccctggc ctcacaacca cagagtcccg ccagcagccc 2520 atggccctgg ctgtggccct gaccaagggt ggagaggccc gaggggagct gttctgggac 2580 gatggagaga gcctggaagt gctggagcga ggggcctaca cacaggtcat cttcctggcc 2640 aggaataaca cgatcgtgaa tgagctggta cgtgtgacca gtgagggagc tggcctgcag 2700 ctgcagaagg tgactgtcct gggcgtggcc acggcgcccc agcaggtcct ctccaacggt 2760 gtccctgtct ccaacttcac ctacagcccc gacaccaagg tcctggacat ctgtgtctcg 2820 ctgttgatgg gagagcagtt tctcgtcagc tggtgttaa 2859

<210> 39 <211> 1958 <212> DNA <213> Artificial Sequence <220 <223> Hamster rpS21 promoter <400 39 gatcaacatt tacgctggct gttttaatga gagcaccggt cttgggtcac ctcactgtca 60 cattggatga ggacccagta agtgctgaga gccgcagatg tagccggtgt gggtgaatgc 120 tgggctggtg tctgctggtc aaggtaccag aggctgcctc agcttcctca gagggacaaa 180 gggtcattaa cactgaggag gcttgtttat tagtttactc ttttctttcc acctaaaagt 240 ttgagctttt ctattagtgc tacaagtatg catcatggtc tgcttctcgt gaaggttttg 300 agcagatgga acacattcta tgaaaacccc tatcacaacc ctgtctacta attctaaact 360 ctgagtcagt cctgggtcag tttcaacggg ctgttctttc tctcattagt ggccatattc 420 ccttgctgtt ggatttggca gtctctgagt ggataccaga aaatacgatt ttttcctttg 480 ttgtgggctt catgctgcct ttgtgttccg tttttttttt tttggggggg gggatgtggt 540 ggagttattt ggtaatactt tgacccttgc aggccctgtt tttatgatgt tagggggccc 600 taggcattgt tcagggcagt tactggaggc tagacctttc tcaacactct aacccagtgc 660 tatgtgcact aaactttttc acctgtttcc agtccctgcc ctttttagga ctgctgaatt 720 tgctgagtag agctactgca aatttctggg gttttccttg gccactttct ccttactggc 780 actctgggtg tgctccatct ctggccacta aagagacctt cagggttcaa ctcaacacac 840 acaggtgcag ctctcaaagc taaaacacaa acaaaccacc cttgtacaca ggcctcatgg 900 ccttccaagg gcagtggcta tggttcttgt ttctgatgca cagaaagggt ctagtggaaa 960 ttccagacac aatgcccaca cctgctttcc caggcgtgag gagggtttca gcagacctca 1020 tgacagtcct gggaaggtgt cgggtgcgcg tggcagggag gggagagctc tccccaagat 1080 catttaactg ggtgtgcaca cctgaggcac cagtctgccc agagagacat caggtgcaca 1140 gttctacaga taagcgagac aagcggtccc tatgtgaaga atgtaacggt aggaaaacca 1200 acagtgtaga ctgggagtct tgtgtccggg ctggtutgca gcctcttcaa cagggggctg 1260 cctgagcgtt aggggcattt tcctcctggt ttttaaagat tttatttgtt atgtagacag 1320 tgtactgcac cctctgggca gactcacaac actgggcggc cggatgccgt gctggccaga 1380 gcaggagagg gcagggcctg ggtggagacg ccgcagggga gcgcgccggc ccggacgcct 1440 ggctggtctc ggcggttccc actggactgc cgctctgctg acacccgtgc ccgcctccct 1500 ccgccgcgac tggcggcggc ttccggggag cgatttccag gtgcaggtct ggggtgtcgg 1560 cgtccccgca ggcgagccgg ctcccttcga cgtccttcct atcccgcgcc cccgccgccc 1620 cccgccgccc cctcaacctc aagcagggga gacccggccg gggcggggca cgaagagcgc 1680 ggcggctcct gctgtgggcg gagctctcct gctatgggcg gagctggggg cggagccgcc 1740 ttggtagggt agagccaggc tccagtgtct gagcctttgt gcggaagagc cggggcttct 1800 ttgcaccgga agcggaagaa aagactccca agccggcctc cggaacggtg gatacgagca 1860 tcgtgacccg gaagtattca ccacacgcac cgcccctccc gcccaagaga gctgcctggg 1920 gacgacccac ttcctttctg cgctccgctg gcctagag 1958

<210> 40 <211> 26 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic primer <400> 40 agctctaata cgactcacta tagggc 26

<210> 41 <211 >21 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: synthetic primer <400> 41 ctctaggcca gcggagcgca g 21

Claims 1. An isolated ß-actin promoter that is chosen from the nucleotide sequences set forth in SEQ ID NOs: 1 or 3, or a variant thereof having promoter activity, wherein said variant is a nucleotide sequence having at least 95% identity to a nucleotide sequence set forth in SEQ ID NO: 1 or 3 over the entire length of that reference sequence. 2. An isolated promoter according to claim 1, wherein said promoter is the nucleotide sequence set forth in SEQ ID NO: 1, or a variant thereof having promoter activity, wherein said variant is a nucleotide sequence having at least 95% identity to the nucleotide sequence set forth in SEQ ID NO: 1 over the entire length of SEQ ID NO: 1. 3. An isolated promoter according to claim 2, wherein said promoter is a variant of the nucleotide sequence set forth in SEQ ID NO: 1, and wherein said variant is a nucleotide sequence having at least 97% identity to the nucleotide sequence set forth in SEQ ID NO: 1 over the entire length of SEQ ID NO: 1. 4. An isolated promoter according to claim 1, wherein said promoter is the nucleotide sequence set forth in SEQ ID NO: 3, or a variant thereof having promoter activity, wherein said variant is a nucleotide sequence having at least 95% identity to the nucleotide sequence set forth in SEQ ID NO: 3 over the entire length of SEQ ID NO: 3. 5. An isolated promoter according to claim 4, wherein said promoter is a variant of the nucleotide sequence set forth in SEQ ID NO: 3, and wherein said variant is a nucleotide sequence having at least 97% identity to the nucleotide sequence set forth in SEQ ID NO: 3 over the entire length of SEQ ID NO: 3. 6. A vector comprising the promoter of any one of claims 1-3, 4 or 5. 7. The vector of claim 6, wherein said vector comprises the promoter of claim 2 or claim 3. 8. The vector of claim 6 or claim 7, wherein said promoter is operably linked to a heterologous nucleic acid. 9. The vector of claim 8, wherein said heterologous nucleic acid encodes a therapeutic protein. 10. The vector of claim 9, wherein said therapeutic protein is selected from the group consisting of acid sphingomyelinase, a-glucosidase, and tissue plasminogen activator. 11. A host cell transfected with the vector of any one of claims 6-10. 12. The host cell of claim 11, wherein said host cell is a Chinese Hamster Ovary (CHO) cell. 13. A method of producing a protein, wherein said method comprises: (a) culturing a host cell transfected with a vector comprising a promoter according to anyone of claims 1-3, or 5, wherein said promoter is operably linked to a nucleic acid molecule encoding said protein; and (b) recovering said protein. 14. The method of claim 13, wherein the protein is an antibody. 15. The method of claim 14, wherein the antibody binds to a TGF-ß family member. 16. The method of claims 13, wherein the protein is a therapeutic protein. 17. The method of claim 16, wherein the therapeutic protein is selected from the group consisting of acid sphingomyelinase, a-glucosidase, and tissue plasminogen activator. 18. A non-human transgenic animal comprising the vector of any one of claims 6-10.

Patentansprüche 1. Isolierter ß-Actin-Promotor, der aus den Nukleotidsequenzen gemäß SEQ ID NO: 1 oder 3 gewählt ist, oder eine Variante davon mit Promotoraktivität, wobei es sich bei der Variante um eine Nukleotidsequenz handelt, die wenigstens 95% Identität mit einer Nukleotidsequenz gemäß SEQ ID NO: 1 oder 3 über die gesamte Länge dieser Referenzsequenz aufweist. 2. Isolierter Promotor nach Anspruch 1, wobei es sich bei dem Promotor um die Nukleotidsequenz gemäß SEQ ID NO: 1 handelt, oder eine Variante davon mit Promotoraktivität, wobei es sich bei der Variante um eine Nukleotidsequenz handelt, die wenigstens 95% Identität mit der Nukleotidsequenz gemäß SEQ ID NO: 1 über die gesamte Länge von SEQ ID NO: 1 aufweist. 3. Isolierter Promotor nach Anspruch 2, wobei es sich bei dem Promotor um eine Variante der Nukleotidsequenz gemäß SEQ ID NO: 1 handelt und wobei es sich bei der Variante um eine Nukleotidsequenz handelt, die wenigstens 97% Identität mit der Nukleotidsequenz gemäß SEQ ID NO: 1 über die gesamte Länge von SEQ ID NO: 1 aufweist. 4. Isolierter Promotor nach Anspruch 1, wobei es sich bei dem Promotor um die Nukleotidsequenz gemäß SEQ ID NO: 3 handelt, oder eine Variante davon mit Promotoraktivität, wobei es sich bei der Variante um eine Nukleotidsequenz handelt, die wenigstens 95% Identität mit der Nukleotidsequenz gemäß SEQ ID NO: 3 über die gesamte Länge von SEQ ID NO: 3 aufweist. 5. Isolierter Promotor nach Anspruch 4, wobei es sich bei dem Promotor um eine Variante der Nukleotidsequenz gemäß SEQ ID NO: 3 handelt und wobei es sich bei der Variante um eine Nukleotidsequenz handelt, die wenigstens 97% Identität mit der Nukleotidsequenz gemäß SEQ ID NO: 3 über die gesamte Länge von SEQ ID NO: 3 aufweist. 6. Vektor, umfassend den Promotor nach einem der Ansprüche 1 - 3, 4 oder 5. 7. Vektor nach Anspruch 6, wobei der Vektor den Promotor nach Anspruch 2 oder Anspruch 3 umfasst. 8. Vektor nach Anspruch 6 oder Anspruch 7, wobei der Promotor in operativer Verknüpfung mit einer heterologen Nukleinsäure steht. 9. Vektor nach Anspruch 8, wobei die heterologe Nukleinsäure für ein therapeutisches Protein codiert. 10. Vektor nach Anspruch 9, wobei das therapeutische Protein aus der aus saurer Sphingomyelinase, α-Glucosidase und Gewebe-Plasminogenaktivator bestehenden Gruppe ausgewählt ist. 11. Wirtszelle, transfiziert mit dem Vektor nach einem der Ansprüche 6-10. 12. Wirtszelle nach Anspruch 11, wobei es sich bei der Wirtszelle um eine CHO(Chinese Hamster Ovary )-Zelle handelt. 13. Verfahren zur Herstellung eines Proteins, wobei das Verfahren (a) das Kultivieren einer mit einem einen Promotor nach einem der Ansprüche 1 - 3, 4 oder 5 umfassenden Vektor transfizierten Wirtszelle, wobei der Promotor in operativer Verknüpfung mit einem für das Protein codierenden Nukleinsäuremolekül steht; und (b) das Gewinnen des Proteins umfasst. 14. Verfahren nach Anspruch 13, wobei es sich bei dem Protein um einen Antikörper handelt. 15. Verfahren nach Anspruch 14, wobei der Antikörper an ein Mitglied der TGF-ß-Familie bindet. 16. Verfahren nach Anspruch 13, wobei es sich bei dem Protein um ein therapeutisches Protein handelt. 17. Verfahren nach Anspruch 16, wobei das therapeutische Protein aus der aus saurer Sphingomyelinase, α-Glucosi-dase und Gewebe-Plasminogenaktivator bestehenden Gruppe ausgewählt ist. 18. Nichtmenschliches transgenes Tier, umfassend den Vektor nach einem der Ansprüche 6-10.

Revendications 1. Promoteur de ß-actine isolé, qui est choisi parmi les séquences nucléotidiques indiquées dans les SEQ ID n° : 1 ou 3, ou variant de celui-ci ayant une activité de promoteur, dans lequel ledit variant est une séquence nucléotidique ayant une identité, d’au moins 95%, avec une séquence nucléotidique indiquée dans les SEQ ID n° : 1 ou 3 sur la totalité de la longueur de cette séquence de référence. 2. Promoteur isolé selon la revendication 1, dans laquelle ledit promoteur est la séquence nucléotidique indiquée dans la SEQ ID n° : 1 ou un variant de celui-ci ayant une activité de promoteur, dans laquelle ledit variant est une séquence nucléotidique ayant une identité, d’au moins 95%, avec la séquence nucléotidique indiquée dans la SEQ ID n° : 1 sur la totalité de la longueur de la SEQ ID n° : 1. 3. Promoteur isolé selon la revendication 2, dans laquelle ledit promoteur est un variant de la séquence nucléotidique indiquée dans la SEQ ID n° : 1, et dans laquelle ledit variant est une séquence nucléotidique ayant une identité, d’au moins 97%, avec la séquence nucléotidique indiquée dans la SEQ ID n° : 1 sur la totalité de la longueur de la SEQ ID n° : 1. 4. Promoteur isolé selon la revendication 1, dans laquelle ledit promoteur est la séquence nucléotidique indiquée dans la SEQ ID n° : 3, ou un variant de celui-ci ayant une activité de promoteur, dans laquelle ledit variant est une séquence nucléotidique ayant une identité, d’au moins 95%, avec la séquence nucléotidique indiquée dans la SEQ ID n° : 3 sur la totalité de la longueur de la SEQ ID n° : 3. 5. Promoteur isolé selon la revendication 4, dans laquelle ledit promoteur est un variant de la séquence nucléotidique indiquée dans la SEQ ID n° : 3, et dans laquelle ledit variant est une séquence nucléotidique ayant une identité, d’au moins 97%, avec la séquence nucléotidique indiquée dans la SEQ ID n° : 3 sur la totalité de la longueur de la SEQ ID n° : 3, 6. Vecteur comprenant le promoteur selon l’une quelconque des revendications 1 à 3, 4 ou 5. 7. Vecteur selon la revendication 6, dans laquelle ledit vecteur comprend le promoteur selon la revendication 2 ou la revendication 3. 8. Vecteur selon la revendication 6 ou la revendication 7, dans laquelle ledit vecteur est lié, de manière opérationnelle, à un acide nucléique hétérologue. 9. Vecteur selon la revendication 8, dans laquelle ledit acide nucléique hétérologue code pour une protéine thérapeutique. 10. Vecteur selon la revendication 9, dans laquelle ladite protéine thérapeutique est choisie dans le groupe constitué par la sphingomyélinase acide, la a-glucosidase ainsi qu’un activateur du plasminogène tissulaire. 11. Cellule hôte transfectée avec le vecteur selon l’une quelconque des revendications 6 à 10. 12. Cellule hôte selon la revendication 11, dans laquelle ladite cellule hôte est une cellule d’ovaire de hamster chinois (CHO). 13. Procédé de production d’une protéine, dans lequel ledit procédé comprend les étapes consistant à : (a) cultiver une cellule hôte étant transfectée avec un vecteur qui comprend un promoteur, selon l’une quelconque des revendications 1 à 3, 4 ou 5, dans lequel ledit promoteur est lié, de manière opérationnelle, à une molécule d’acide nucléique qui code pour ladite protéine ; et (b) récupérer ladite protéine. 14. Procédé selon la revendication 13, dans laquelle la protéine est un anticorps. 15. Procédé selon la revendication 14, dans laquelle l’anticorps se lie à un membre de la famille du TGF-ß. 16. Procédé selon la revendication 13, dans laquelle la protéine est une protéine thérapeutique. 17. Procédé selon la revendication 16, dans laquelle la protéine thérapeutique est choisie dans le groupe constitué par la sphingomyélinase acide, la a-glucosidase ainsi qu’un activateur du plasminogène tissulaire. 18. Animal transgénique non humain comprenant le vecteur selon l’une quelconque des revendications 6 à 10.

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader’s convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description • US 60480768 B [0112]

Non-patent literature cited in the description • FERNANDEZ. Gene Expression Systems. Academic Press, 1999 [0002] • XU et al. Gene, 2001, vol. 272, 149-156 [0003] • SMIRNOVA et al. Bioorg. Khim., 2000, vol. 26 (5), 392-396 [0004] • BEDDINGTON R S P et al. Development, 1989, vol. 106, 37-46 [0005] • BREITBART A S et al. Annals of Plastic Surgery. December 1999, vol. 43, 632-639 [0006] • NUDEL U et al. Nucleic Acids Research, 1983, vol. 11 (6), 1759-1771 [0007] • ELDER P K et al. Molecular and Cellular Biology, January 1988, 480-485 [0009] • BRADFORD. Anal. Biochem., 1976, vol. 72, 248 [0021] • SAMBROOK et al. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, 1989 [0023] • VALCULESCO et al. Science, 1995, vol. 270, 484-487 [0037] • VALCULESCO et al. Cell, 1987, vol. 88, 243-251 [0037] • BONNER étal. J. Mol. Biol., 1973, vol. 81,123 [0037] • HOWLEY et al. J. Biol. Chem., 1979, vol. 254, 4876 [0038] • AUSUBEL et al. Current Protocols in Molecular Biology. John Wiley &amp; Sons, 1995 [0039] • SAMBROOK et al. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Press, 1989 [0039] • DEVEREUX et al. Nucl. Acids. Res., 1984, vol. 12, 387 [0043] • TATUSOVA et al. FEMS Microbiol. Lett., 1999, vol. 174, 247 [0043] • COLE et al. Biotechnology, 1993, vol. 11,1014-1024 [0098] • SENGER et al. Biotechnology Progress, 2003, vol. 19, 1199-1209 [0101] • DOWD et al. Biotechnology Progress, 2000, vol. 16, 786-794 [0101]

Claims (3)

1. Ö5 bstamkíin és RFS21 protnóterek és alkaim<vásmk Sztsbndttimi àgêtiyp»B.s«k Ϊ^ΡΜΙί; (Bakiin proroôier, |ρ el* !D NY); { vagy H szerinti , JjjL profnöíer-akíiv-íösD var-áí-ssi közét ven tstváserztvu, ahoi a variáns olyan nukientu^szekvenckt, amely iegaíább ' ' ' v\ noss !;-λ ' Suv Ν'' ' V' ' J 5> κ'νον ο wkui'x kîî c·.·"'' >ν'!;·ί· m --'«ivóm s \ hs>ssz:ósá;gársíí vonarKozí&amp;iva. >. Az I. igénypont s»r*ni izolált prompten ahol a pnmto* &amp; k$:q n> N«): I s/er?m· ntskleotkl-· ^wUriHinvd pornóiét .sksomnm so!*,n«n vw a satum, !myun\k"zek\. mw mvN.seb 'k'm a/mvavom a SEQ 5D NO: I szerinti nukteotks^zekveRdavas a Sk-IQ p^ ; s?;»rinii szekvencia tolj«® hosszúságára vonatkoztatva. λ Λ 2. Igénypont saninri i*olák |*om<kcn ahol a gromo,er a seq id ^O: t szerinti oukleoitá« saakí.mem t után Λ -üu'î ,: 'S' *«t's nők Y o, J - -\xx, nota :'v, «um. "o«5 m., St 0 ;0 NO. : men·";! «Ä-tÄ^ ;-s:x«s:ídti· 's^sk:veëê^ ;
2. 4, Az I. igénypont ϊζ«)* sztnait promoter, ahol a ortm-okr a SilQ 1D MG: 3 szerinti stukieotid-sevkveuma vagv pnuBoVrmhttvmN!.! \ mánnk ah* >3 a műim., nukknölms.mvvmxr'; iegmshb *M'e ttAnmwgu a SBQ H> NO: 3 szeri«« nvikterffetaKk veocttval a i>pq iq HO; 3 «;í.ednti szekvencia teljes hosszúságára Sv .$'''4;· ù^æypôt®: fromátsty aboi g:protpotsh·: tr SEC* © N0: 5 szetpli «oklpotki- szekvestets va: «mss, es tstK-l a \ ^rsáns ism nvno szer vénein k-gmabb ^t"'u «.vrosaagn : >1 (.· it i %Y ' ' szerion '$yïâéô«ô»SJBek'WHSàvai a S£Q iu No, a szerson rzekvoncja teljes hosszúságéra vonatkoztatva. o. \ ekn«'. «mots -.a ' ',4 :>·ό> '' lïcotvo-îtok tarojcKiko ^ζοποι! ρ>ν«ηο\{5 töitaiottz 7, /\ ;>. igénypont szerinti vektor ahol n vektor 2. vagy ). igénypont szerinti psomótert tartalmaz 8, A 6. vagy ?. igénypoist szerinti vektor, ahol a pmtnóter működőképesét! kapcsolt iteterolég rsnkicinsavhoz. *í tg ^ \ \n s '»!>* ^'k'<. Out '"eto>^\^ vKet'v \ ' u v e uk\v Itk A 9 ieényooftí szőrit!« tek tor, ahoi a terápiás protêt:: ? következők ált«: alkotott csoporthéí van feiWÉ' sz«Bgôtsiéil«â^^gÂ<MtïftZ·: ás szövőt! pl&amp;Zütinogén akilvátor. ; ; ; H, Gazdat.ett, amely a 6-tO. Igénypotítt^ bármelyike szert «ti vektorra! van transztsktálva U X !' eh NVt ' o. m Ov!μ 4v ka' V \' ' S(<\ e" *< IP gtisnls psvueln eHtáintás&amp;ra. ahol nz eiloius magábsn lágiaijn: (a; az. :~3. vagy ?. sgénypontok ............. ,mmm\a·: m.« m«zv '-vk, »a' tvmm rkmlt v \h\,' swvcO öm! a t\am<'e: működőképesért kapcsolt a proteint kódoló auste»v -mokkulávai; és (bt- n protein visszanyetését. 54. Λ 13. incnypont szetimi eljárás, ahol a protein ellenanyag. 55. A 14. iíénvpotn. szerints eljárás, altot az ellenanyag Γ0Ι-Γ> csaiadtagho/ kötikbk. : : A iy i^nvponr szerinti élj áras, iaftti p ptxttd:· tétápíákptx>teln. j j N 5 7 a tó joenvpotsf szennti eljárás, altoi a terápia* protein a következők által alKoimt caofxmbôl van kiválasztva, sröngotnioitttász, tt-ginkozidáz és ^yetiplazmtno^n akítvator.
3. 18, Nent-bonsé« trttnszgzntktts tlitnt. antelt 6-10. igeutypontm. bértm-Ktke szetinti sektort Iwtaitna?.